

33rd ANNUAL REPORT 2018 - 2019



COMBAT DRUGS LIMITED

**Regd Office: 4th Floor, Plot No. 94, Sagar Society,
Road No. 2, Banjara Hills, Hyderabad,
Telangana-500034. India.
Email: info@combatdrugs.in URL: www.combatdrugs.in**

33rd ANNUAL GENERAL MEETING

Date : 09-12-2019

Day : MONDAY

Time : 11.00 AM

Venue : 1st Floor, Conference Hall,
Goodlands Banquet, Opp. CCMB
Habsiguda X Roads,
Hyderabad-500 007. T.S., INDIA

CONTENTS

Notice	3
Director's Report	27
Management Discussion and Analysis	42
Report on Corporate Governance	45
Standalone Auditor's Report	76
Standalone Financial Statements	86
Consolidated Auditor's Report	106
Consolidated Financial Statements	115
Consent Form	145
Proxy Form/ Attendance Slip	146
Polling Papers	147

No Gifts will be distributed at the meeting.

COMBAT DRUGS LIMITED

CIN NO: CL23230TG1986PLC006781

BOARD OF DIRECTORS

Mr. Vasudev Kommaraju	Director
Mr. Sushant Mohan Lal	Director
Mrs. Vemuri Shilpa	Independent Director
Mr. Ragu Raghuram	Independent Director

Registered/ Corporate Office:

Plot No. 94, 4th Floor, Road No. 2,
Sagar Society, Banjara Hills,
Hyderabad ,500034. TS
Website:www.combatdrugs.in
Phone: 040-48536100

Works:

9-109/9, Plot No.112, Rd.No.14,
Gayatri Nagar, Boduppal,
Hyderabad, 500039. TS
E-mail: Info@combatdrugs.in

Compliance Officer:

Chief Financial Office:

Mr. Kumar Raghavan

Mrs. Sonam Jalan

Bankers

Axis Bank Ltd,
Banjara Hills Branch,
Hyderabad, TS, India.

Karnataka Bank Ltd
Raj Bhavan Road Branch,
Hyderabad, TS, India

Auditors

M. Anandam & Co.
Chartered Accountants
Secunderabad, TS. India

Legal Advisor

N.Rajeshkar Reddy, Advocates
Chitra Layout, L.B, Nagar,
Karnataka Bank Limited
Hyderabad, TS, India.

REGISTRARS & TRANSFER AGENTS

**M/s VENTURE CAPITAL & CORPORATE SERVICES PRIVATE LIM-
ITED**

12-10-167, BHARAT NAGAR, HYDERABAD-500 018, TELANGANA
Phone: (+91)-4023818475/476 Email id: info@vccipl.com

NOTICE

Notice is hereby given that the Thirty Third Annual General Meeting of the members of Combat Drugs Limited will be held on Monday, the 9th day of December, 2019 at 11.00 A.M. at 1st Floor, Conference Hall, Goodlands Banquets, Opp. CCMB, Habsiguda X Roads, Hyderabad-500007. Telangana INDIA to transact the following items of business:

ORDINARY BUSINESS:

Item No. 1 – Adoption of Audited Standalone and Consolidated Financial Statements

To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2019 together with the Reports of the Board of Directors and the Auditors thereon.

Item No. 2 - APPOINTMENT OF AUDITORS

To consider and if thought fit to pass the following resolution with or without modification(s) as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 139 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof for the time being in force), M/s M. Anandam & Company, Chartered Accountants, be and are hereby appointed as Auditors of the Company to hold the office from the conclusion of this Annual General Meeting of the Company until the conclusion of the next Annual General Meeting at a remuneration to be fixed by the Board of Directors in consultation with the Auditors.”

Special Business:

Item No. 3 - RE-APPOINTMENT OF Mr. RAGU RAGHURAM AS INDEPENDENT DIRECTOR

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 149, 150 and 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 and Companies (Appointment and Qualifications

of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Sri Ragu Raghuram having Director Identification Number 03567941 who was appointed as an Independent / non-executive Director of the Company, who has submitted a declaration that he meets the criteria for independence as provided in Section 149(6) of the Act and who is eligible for appointment, be and is hereby appointed as an Independent Director of the Company

Item No. 4 - RE-APPOINTMENT OF MRS.VEMURI SHILPA AS AN INDEPENDENT DIRECTOR

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 149, 150 and 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 and Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Mrs. Vemuri Shilpa having Director Identification Number 07140155 who was appointed as an Independent / non-executive Director of the Company, who has submitted a declaration that she meets the criteria for independence as provided in Section 149(6) of the Act and who is eligible for appointment, as an Independent Director of the Company.

Item No. 5 - RE-APPOINTMENT OF SRI SUSHANT MOHANLAL AS DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Special Resolution:

“RESOLVED THAT pursuant to provisions of Sections 160, 161,196, 197 and 203 read with Schedule V and other applicable provisions, if any, of the Companies Act 2013, as amended from time to time thereto and the Articles of Association of the Company, and subject to such permissions, consents, and approvals from various other authorities, as may be necessary, and subject to such modifications, variations, conditions as may be imposed by them while granting their approved permissions, consents and approvals the approval of the shareholders of the Company be and is hereby accorded for the appointment of Sri Sushant Mohanlal as Director of the Company, for a period of One year

and payment of remuneration for the aforesaid period on the following terms and conditions, as approved by the Nomination & Remuneration Committee.

1. BASIC: Rs.1,00,000/- per month
2. PERQUISITES

In addition to the salary as stated above Sri Sushant Mohanlal shall be entitled to the following perquisites

- i) Contributions by the Company to Provident Fund as per the rules of the Company.
- ii) Annual Leave travel concessions for self and family
- iii) Other Perks as deemed fit by the Board from time to time

RESOLVED FURTHER THAT in the event of loss or inadequacy of profits in any financial year during the currency of tenure of the appointment, the Director shall be paid salary, perquisites and other allowances as set out herein above and the Explanatory Statement, as the minimum remuneration, subject to ceiling as specified in Schedule V of the Companies Act, 2013 from time to time.

RESOLVED FURTHER THAT any Director of the Company be and are hereby authorised to take such steps and do all other acts, deeds and things as may be necessary or desirable to give effect to this resolution.”

Item No. 6 - Approval for change of name of the Company and consequent amendment to Memorandum of Association and Articles of Association and other documents of the Company:

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“**RESOLVED THAT** pursuant to the provisions of Section 4,5,13,14 and all other applicable provisions, if any, of the Companies Act, 2013, read with applicable Rules and Regulations framed thereunder (including any statutory modification(s), clarification(s), substitution(s) or re-enactment(s) thereof for the time being in force), any other applicable law(s), regulation(s), guideline(s), the provisions of the Memorandum and Articles of Association of the Company and the uniform listing agreement entered by the Company with BSE Limited (the “Stock Exchange”) and subject to the approvals, consents, sanctions and permissions of the Central Government/ Stock Exchange(s)/appropriate regulatory and statutory

authorities/ departments as may be necessary, consent of the members of the Company be and is hereby accorded for changing the name of the Company from “Combat Drugs Limited” to “Decipher Labs Limited” or any other name as approved by the Registrar of Companies.

RESOLVED FURTHER THAT the name “ Combat Drugs Limited” wherever it occurs in the Memorandum and Articles of Association of the Company be substituted by the name “Decipher Labs Limited.”

RESOLVED FURTHER THAT all the Directors of the Company be and are hereby severally authorized to sign and file all the necessary e-forms and other documents with any statutory authorities and to do all such acts, deeds, things and matters as may be required or necessary in this matter on behalf of the Company.”

Item No. 7 - INCREASE OF AUTHORISED SHARE CAPITAL

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“**RESOLVED THAT** pursuant to provision of Section 61(1)(a) of the Companies Act, 2013, and any other applicable provisions and the relevant rules framed there under and in accordance with the provisions of the Articles of Association of the Company, the Authorised Share Capital of the Company be and is hereby increased from Rs. 8,00,00,000/- (Rupees Eight Crores only) divided into 80,00,000 (Eighty Lakh) Equity Shares of Rs. 10/- each to Rs. 10,50,00,000/- (Rupees Ten Crores Fifty Lakhs only) divided into 1,05,00,000 (One Crore Five Lakh) Equity Shares of Rs. 10/- each.

RESOLVED FURTHER THAT the Clause No. V of Memorandum of Association of the Company be altered as below:

Clause V:

V. The Authorised Share Capital of the Company is Rs.10,50,00,000/- (Rupees Ten Crore Fifty Lakhs Only) divided into 1,05,00,000 Equity Shares of Rs.10/- (Rupees Ten Only) each, each with powers to increase or reduce or vary the capital of the Company and/or the nominal value of the shares and power to divide the shares in the capital for the time being into several classes and attach thereto respectively such preferential, special rights, privileges, conditions or restrictions as may

be determined by or in accordance with the Articles of Association of the Company and to vary, modify or abrogate any such rights, privileges, conditions or restrictions in such manner as may, for the time being, be provided by the Articles of Association of the Company subject to the provisions of the law for the time being in force.”

FURTHER RESOLVED THAT the consent of the Company be and is hereby accorded pursuant to provisions of Section 14 of the Companies Act, 2013 to alter the existing article 3 of Articles of Association of the Company by substituting the following as mentioned here under:

“The authorized share capital of the company shall be such amount as may from time to time be authorized as per clause V of the Memorandum and the securities shall carry the rights, privileges and conditions attached thereto as per the relevant provisions contained in that behalf in these presents and with power to the Company to increase or reduce the capital and to divide the shares in the capital for the time being into several classes (being those specified in the Companies Act, 2013) and to attach thereto respectively such preferential, qualified or special rights, privileges or conditions as may be determined by or in accordance with the Articles of Association of the Company and to vary, modify, enlarge or abrogate any such rights, privileges or conditions in such manner as may be permitted by the said Act or provided by these Articles of Association of the Company”

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby severally authorized to take necessary steps for the purpose of making e-filings for registration of the amendment to the Memorandum of Association with Registrar of Companies and to do all such, deeds as may be required to give effect to the aforesaid resolution.”

Item No. 8. ISSUE OF EQUITY SHARES ON PREFERENTIAL BASIS (SWAP) FOR ACQUISITION OF DECIPHER SOFTWARE SOLUTIONS LLC.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“**RESOLVED THAT** in terms of Sections 23, 42 and 62(1)(c) of the Companies Act, 2013 and all other applicable provisions, if any, (including any statutory modification(s) or re-enactments thereof for the time being in force), Memorandum and Articles of Association of the Company,

SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 and Listing Agreement entered into by the Company with the Stock Exchange where the Company's Shares are listed and in accordance with the provisions of the SEBI (Issue of Capital and Disclosures Requirements), Regulations 2018 as amended ("the ICDR Regulations), the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, as amended (the "SAST Regulations"), as may be applicable to the preferential issue of Equity Shares and other applicable regulations of SEBI, if any, (including any statutory modification(s) or re-enactments thereof for the time being in force), Foreign Exchange Management Act, 2000 and rules and regulations as may be prescribed by the RBI and subject to such conditions and modifications as may be considered appropriate by the Board of Directors of the Company (hereinafter referred to as the "Board" which term shall include any committee thereof for the time being to which all or any of the powers hereby conferred on the Board by this resolution, have been delegated) such consents and approvals of SEBI, Stock Exchanges, ROC, RBI, or such other bodies or authorities as may be required by law and as may be necessary and subject to such conditions and modifications as may be prescribed by any of them while granting any such approvals, consents, permissions and/or sanctions and which may be agreed to by the Board, the consent of the members of the company be and is hereby accorded to the Board to offer, issue, and allot in one or more tranches up to 21,00,000 (Twenty One Lakh) Equity Shares of Rs. 10/- each at a price of Rs. 40/- (including a premium of Rs. Thirty Only) per Equity Share or price as on relevant date whichever is higher to the persons as mentioned in the explanatory statement determined by the Board in accordance with the provisions of Chapter VII of SEBI (ICDR) Regulations, 2009, SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 (including any statutory modification(s) and subsequent amendments thereof, towards consideration for acquisition of 100% stake in DECIPHER SOFTWARE SOLUTIONS LLC through swapping after valuation done by Merchant Banker/ Valuer ”.

“RESOLVED FURTHER THAT the pricing of the Equity Shares to be allotted is in accordance with the SEBI's Preferential Issue Guidelines. However, the issue price shall in no case be less than the price determined as per the Preferential Issue Regulations as provided in Chapter VII of SEBI (ICDR) Regulations, 2009.”

“RESOLVED FURTHER THAT the “Relevant Date”, SEBI (ICDR) Regulations would be 8th November, 2019, as 9th November, 2019 the

date 30 days prior to the date of this AGM is a weekend day and hence 8th November, 2019 being the day preceding the weekend day, shall be considered as the Relevant Date for the purpose of abovementioned issue of Equity Shares.”

“RESOLVED FURTHER THAT the new Equity Shares issued shall rank pari- passu with the existing Equity Shares of the Company in all respects and that the Equity Shares so allotted during the financial year shall be entitled to the dividend, if any, declared including other corporate benefits, if any, for which the book closure or the Record Date falls subsequent to the allotment of Equity Shares.”

“RESOLVED FURTHER THAT the aforesaid Equity Shares allotted in terms of this resolution shall be subject to lock-in requirements as per the provisions of Chapter VII of SEBI (ICDR) Regulations, 2009.”

“RESOLVED FURTHER THAT the allottees will swap their proposed Equity Shares stake in DECIPHER SOFTWARE SOLUTIONS LLC to the company as the consideration for preferential issue.”

“RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to determine, vary, modify the price, alter any of the terms and conditions of the issue, if necessary, keeping in view the provisions of various Acts, Rules and Regulations in force from time to time.”

“RESOLVED FURTHER THAT the Company do apply for In-Principle Approval, Prior to Issue and Allotment of Equity Shares, and apply for listing of the new Equity Shares on the Stock Exchange and thereby comply with the applicable regulations.”

“RESOLVED FURTHER THAT the Company does make an application to the Depositories for admission of the new Equity Shares.”

“RESOLVED FURTHER THAT the Securities shall be allotted within a period of 15 days from the date of passing of this resolution, provided that if any approval or permissions by any regulatory authority or the Central Government for allotment is pending, the period of 15 days shall be counted from the date of such approval or permission.”

“RESOLVED FURTHER THAT the Board be and is hereby authorized to delegate all or any of the powers herein conferred to any Committee

of Directors or any other officer or officers of the Company to give effect to the aforesaid resolutions.”

“RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, the Board be and is hereby authorized to agree and accept all such condition(s), modification(s) and alteration(s) as may be stipulated by any relevant authorities while according approval or consent to the issue as may be considered necessary, proper or expedient and give effect to such modification(s) and to resolve and settle all questions, difficulties or doubts that may arise in this regard to implementation of this Resolution, issue and allotment of Equity Shares and to do all acts, deeds and things in connection therewith and incidental thereto without being required to seek any further consent or approval of the members of the Company to the intent that the members shall be deemed to have given their approval thereto expressly by the authority of this resolution.”

Item No. 9 - Disinvestment in Overseas Wholly Owned Subsidiary (RA LABS PTE LTD)under Section 180(1)(a) of the Companies Act, 2013:

To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of section 180(1)(a) and other applicable provisions if any, of the Companies Act, 2013, and the relevant rules made thereunder, Regulation 24 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (including any statutory modifications, amendments or re-enactments of any of them for the time being in force), the Memorandum and Articles of Association of the company and subject to other requisite approvals to the extent necessary as may be required, the consent of the members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as Board) to sell/ transfer or otherwise dispose-off in one or more tranches, the entire investments i.e. 7122 shares held in RA LABS PTE LTD., a wholly owned subsidiary company in Singapore, to the purchasers and at the consideration not less than the amount as mentioned below; or to any other purchasers (not being related) with whom the Board may finalise the agreement and on such other terms and conditions as may be approved by the Board:

S.No	Purchaser	No Of Shares	Consideration
1	Janakiram Ajjarapu	7122	at Par ie SGD \$1 totalling SGD 7122

“**RESOLVED FURTHER THAT** for the purpose of implementation of this resolution, the Board be and is hereby authorised to do all such acts, deeds, matter and things, including but not limited to deciding the time, mode, manner, extent of tranches, if required and other terms and conditions of the disinvestment/ sale of the shares as aforesaid, negotiating and finalising the terms of sale/ offer for sale as may be necessary, desirable and expedient to be agreed, and all incidental and necessary steps for and on behalf of the company and to settle all questions or queries that may arise in the course of implementing this resolution.”

By the Order of the Board
For **COMBAT DRUGS LIMITED**

Sd/-

SUSHANT MOHAN LAL
DIRECTOR

Place: Hyderabad
Date: 08.11.2019

NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY. THE PROXIES TO BE EFFECTIVE SHOULD BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LATER THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING. A person can act as a Proxy on behalf of Members not exceeding fifty and holding in aggregate shares not more than 10 per cent of the total Share Capital of the Company. Proxies submitted on behalf of companies must be supported by an appropriate Resolution/ Authority, as applicable.
2. Register of members and share transfer books of the company will remain closed from 30/11/2019 to 09/12/2019 (both days inclusive).
3. The relevant Statement, pursuant to Section 102(1) of the Companies Act, 2013 ("the Act") in respect of the items of Special Business is annexed hereto.
4. The transfer of listed securities shall not be processed unless the securities are held in the dematerialized form with a depository. Therefore, for effecting any transfer, the securities shall mandatorily require to be in Demat form. Except in case of transmission or transposition of securities, requests for effecting the transfer of securities shall not be processed unless the securities are held in the dematerialized form with a depository.

Members holding shares in physical form are requested to convert their holdings to dematerialized form at the earliest. Members can contact the Company or Venture Capital and Corporate Investments Private Limited (VCCIPL) for assistance in this regard.

Members holding shares in physical form should strive to convert to demat form failing which, submit their PAN and Bank details to the Share Department of the Company/Registrar and Share Transfer Agent, Venture Capital and Corporate Investments Private Limited (VCCIPL).

Members holding shares in electronic form are requested to update the PAN and Bank details with their depository participants with whom they are maintaining their demat accounts.

5. As per the provisions of the Companies Act, 2013, facility for making nomination is available for Members of the Company in respect of shares held by them. The members, who wish to nominate a person, may furnish the required details to the Company in prescribed form.
6. To support the 'Green Initiative', Members who have not registered their e-mail addresses are requested to register the same with DPs / VCCIPL. Members are requested to provide their e-mail address with DP ID/Client ID / Folio No. by sending email at investorinfo@combatdrugs.in / info@vccipl.com and ensure that the same is also updated with their respective DP for their demat account(s). The registered e-mail address will be used for sending future communications.
7. Electronic copy of the Notice of the 33rd Annual General Meeting of the Company inter alia indicating the process and manner of E-voting along with Attendance Slip and Proxy Form is being sent to all the members whose email Ids are registered with the Company/ Depository Participant(s) for communication purposes unless any Member has requested for a hard copy of the same. For Members who have not registered their Email address, physical copies of the Notice of the 33rd Annual General Meeting of the Company inter alia indicating the process and manner of E-voting along with Attendance Slip and Proxy Form is being sent in the permitted mode. Members may also note that the Notice of the 33rd Annual General Meeting and the Annual Report for 2018-19 will also be available on the Company's website www.combatdrugs.in for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office in Hyderabad for inspection between 2:00 p.m. to 4:00 p.m. on all working days from Monday to Friday. Even after registering for E-communication, Members are entitled to receive such communication in physical form, upon making a request for the same, by post, free of cost. For any communication, the Members may also send requests to the Company or to its Registrar and Share Transfer Agent, at the following Email ID: info@vccipl.com / investorinfo@combatdrugs.in

8. VOTING THROUGH ELECTRONIC MEANS

In compliance with the provisions of the Listing Agreement read with Section 108 of the Companies Act, 2013 and the Rule 20 of the Companies (Management and Administration) Rules, 2014, the company is pleased to provide members facility to exercise their votes for all the resolutions detailed in the Notice of the 33rd Annual

Report of the company and the business may be transacted through e-voting. The company has engaged the services of National Depository Services Limited (NDSL) as the authorized agency to provide the e-voting facility. The detailed instructions for E-voting are given as a separate attachment to this Notice.

9. As per requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, particulars relating to appointment and reappointment of Directors are given in the Corporate Governance Section of the Annual Report.
10. Members are requested to quote their Registered Folio No. on all correspondence(s) with the Company.
11. Mr. S. S. Marthi (Membership No.FCS 1989), Practicing Company Secretary, is appointed as scrutinizer to conduct E-voting.

By the Order of the Board
For COMBAT DRUGS LIMITED

Sd/-

SUSHANT MOHAN LAL
DIRECTOR

Place: Hyderabad
Date: 08.11.2019

E-VOTING

Pursuant to Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as substituted by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) executed by the company with the BSE Limited and Secretarial Standard on General Meetings (SS-2) issued by the ICSI, the company is pleased to provide Members the facility to exercise their right to vote at the Annual General Meeting (AGM) by electronic means and the business may be transacted through evoting services provided by National Securities Depository Limited (NSDL).

A Member may exercise his/her votes at any General Meeting by electronic means and Company may pass any resolution by electronic voting system in accordance with Companies (Management and Administration) Amendment Rules, 2015.

During the e-voting period, Members of the Company holding shares either in physical form or dematerialized form, as on the cut-off date (record date) i.e., (November 30, 2019), may cast their votes electronically.

The Company has approached NSDL for providing e-voting services through our evoting platform. In this regard, your Demat Account/Folio Number has been enrolled by the Company for your participation in e-voting on resolution placed by the Company on e-Voting system.

The Notice of the Annual General Meeting (AGM) of the Company inter alia indicating the process and manner of e-Voting process along with printed Attendance Slip and Proxy Form can be downloaded from the link [https:// www.evoting.nsdl.com](https://www.evoting.nsdl.com) or www.combatdrugs.in Voting either through electronic voting system or ballot or polling paper will be available at the meeting for the members attending the meeting who have not casting their vote by remote e voting. Members who have cast their vote by remote e voting prior to the AGM may also attend the meeting but shall not be entitled to cast their vote at the AGM.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholders' section.
3. A new screen will open. You will have to enter your User ID, your Password and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Your password details are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii) If your email ID is not registered, your 'initial password' is communicated to you on your postal address with the Annual Report.
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
- a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/ folio number, your PAN, your name and your registered address.

- d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see the Home page of e-Voting. Click on e-Voting. Then, click on Active Voting Cycles.
2. After click on Active Voting Cycles, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle is in active status.
3. Select “EVEN” of the company “COMBAT DRUGS LIMITED” for which you wish to cast your vote.
4. Now you are ready for e-Voting as the Voting page opens.
5. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/ modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
6. Upon confirmation, the message “Vote cast successfully” will be displayed.
7. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
8. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines and Other Information

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to spcspl@gmail.com with a copy marked to evoting@nsdl.co.in.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details/Password?” or “Physical User Reset Password?” option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800-222-990 or send a request at evoting@nsdl.co.in

4. Any person, who acquires shares of the Company and become member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. November 30, 2019
- a. may obtain the login ID and password by sending a request at evoting@nsdl.co.in.
 - b. A Member may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the AGM.
 - c. The voting rights of Members shall be in proportion to their shares of the paid up equity share capital of the Company.
 - d. Mr. S.S.Marathi, Practicing Company Secretary, has been appointed by the Company to act as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.
 - e. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of ballot paper for all those members who are present at the AGM but have not cast their votes by availing the remote evoting facility.
 - f. The Scrutinizer shall after the conclusion of voting at the General Meeting, will first count the votes cast at the Meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than 48 hours of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
 - g. The results declared along with the Scrutinizer's Report shall be placed on the Company's website viz., www.combatdrugs.in and on the website of NSDL and BSE after AGM.

All the documents referred to in the accompanying Notice and the Statement pursuant to Section 102(1) of the Companies Act, 2013, will be available for inspection at the Registered Office of the Company during business hours on all working days up to date of declaration of the result of the 33rd Annual General Meeting of the Company.

Members holding Equity Shares in Electronic Form and Proxies thereof, are requested to bring their DP ID and Client ID for identification

By the Order of the Board
For COMBAT DRUGS LIMITED

Sd/-

SUSHANT MOHAN LAL
DIRECTOR

Place: Hyderabad
Date: 08.11.2019

Brief profile of Directors Retiring and to be appointed, at the Annual General Meeting of the Company (Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

- i. Name of Director : Mr. RAGU RAGHURAM
DIN : 03567941 Date of Birth: 05/10/1959
Date of Appointment : 30/10/2017 Qualification: MBA
Other Directorship : NIL Expertise: Business Development
Chairman/Members of the Committee in other Companies: NIL
No of shares held in the Company: NIL
- i. Name of Director : Mrs. VEMURI SHILPA
DIN : 07140155 Date of Birth: 28/12/1978
Date of Appointment : 30/03/2015 Qualification: MBA
Other Directorship : NIL Expertise : H.R
Chairman/Members of the Committee in other Companies : NIL
No of shares held in the Company: NIL
- i. Name of Director : Mr. SUSHANT MOHAN LAL
DIN : 01227151 Date of Birth: 07/05/1980
Date of Appointment : 30/10/2017 Qualification: MBA
Other Directorship : NIL Expertise : Marketing
Chairman/Members of the Committee in other Companies : NIL
No of shares held in the Company: 6,55,200

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013.

ITEM NO. 3: Appointment of Mr. Ragu Raghuram as an Independent Director

Mr. Ragu Raghuram was appointed as an Independent Director of the Company pursuant to Section 161 of the Companies Act, 2013, effective from 30th October, 2017 and holds office as director upto the date of ensuing AGM. The Company has received a notice from a member in terms of Section 160 of the Companies Act, 2013 proposing the candidature of Mr.Ragu Raghuram as an Independent Director of the Company liable to retire by rotation along with prescribed deposit of Rs. 1,00,000/

Mr. Ragu Raghuram is not disqualified from being appointed as an Independent Director in terms of Section 164 of the Act and has given his consent to be appointed as a Director. The Board recommends the appointment of Mr.Ragu Raghuram as Independent Director liable to retire by rotation and propose to pass the resolution set out in Item No. 3 of the notice.

Save and except Mr. Ragu Raghuram none of the other Directors and their relatives are in any way, are concerned or interested, financially or otherwise, in the resolution set out in Item No. 3.

ITEM NO.4: Appointment Of Mrs. Vemuri Shilpa as an Independent Director

Mrs. VEMURI SHILPA was appointed as an Independent Director of the Company pursuant to Section 161 of the Companies Act, 2013, effective from 30th March, 2015 and holds office as director retiring by rotation on the date of ensuing AGM. The Company has received a notice from a member in terms of Section 160 of the Companies Act, 2013 proposing the candidature of Mrs. Vemuri Shilpa as an

Independent Director of the Company liable to retire by rotation along with prescribed deposit of Rs.1,00,000/-.

Mrs. Vemuri Shilpa is not disqualified from being appointed as an Independent Director in terms of Section 164 of the Act and has given his consent to be appointed as a Director. The Board recommends the appointment of Mrs. Vemuri Shilpa as Independent Director liable to retire by rotation and propose to pass the resolution set out in Item No. 4 of the notice.

Save and except Mrs. Vemuri Shilpa none of the other Directors and their relatives are in any way, concerned or interested, financially or otherwise, in the resolution set out in Item No. 4.

ITEM NO.5: Appointment of Mr. Sushant Mohan Lal as Director

Mr. Sushant Mohan Lal, is the Director of the company had been appointed for a period of two years and is retiring at the ensuing Annual General Meeting of the company. He has been with the company since 2007 and has been instrumental in guiding the company . It is proposed to appoint him as Director of the company in order to have continuance in the business of the company for a period of 1 year.

Sri Sushant Mohan Lal does not enjoy any special rights through any formal or informal arrangements. The special resolution proposed at Item No.5 is in terms of Regulation 31(5) of SEBI (LODR) Regulations, 2015.

Save and except Sri Sushant Mohanlal none of the other Directors / Key Managerial Personnel and their relatives are in any way, are concerned or interested, financially or otherwise, in the resolution set out in item no. 5.

The Board recommends the appointment of Mr. Sushant Mohan Lal as Director not liable to retire by rotation and proposes to pass the resolution set out in Item No. 5 as Special resolution.

ITEM NO.6: Change of Name of the Company

The Board of Directors of the Company in its meeting held on 12th August, 2019 and 4th November, 2019 decided to change the name of the Company from “COMBAT DRUGS LIMITED” to “Decipher Labs Limited” to bring it in syc with its operating fields and give a global recognition. The Directors believe that the change in the name of the Company which is being undertaken as part of corporate rebranding would make the name of the Company sharp and focused.

It will also reflect the operations of the Company and the proposed software industry of which it is going to be a part. The Company had made an application for reservation of the name change to the Central Registration Centre, MCA and the desired name “Decipher Labs Limited” was made available vide their letter dated 14th October, 2019 to the Company.

If the change of name is approved, share certificates already issued will not be called in for the purpose of exchange into certificates bearing the new name, but will be so exchanged as and when the existing certificates come into the possession of the company and in the meantime the existing certificates will continue to be accepted for all purposes as indicating entitlement to shares of the Company.

The Companies Act, 2013 requires the Company to obtain the approval of members for change of name by way of Special Resolution.

As per the provisions of Sections 13 of the Companies Act, 2013, approval of the shareholders is required to be accorded for changing the name of the Company & consequent alteration in the Memorandum of Association and Articles of Association by way of passing a Special Resolution. Hence, the resolution is put up for shareholders approval.

The Board of Directors recommend passing of the Special Resolution, as set out in Item No.6 of the Notice.

No Director or Key Managerial Personnel of the company has any interest in the resolution set out in the Item No. 6 of the Notice, except as a member, if any, of the Company.

ITEM NO. 7: Increase in the Authorised Capital Of The Company

The present authorised capital of the company is Rs.8,00,00,000/- (Rupees Eight Crores) is divided into 80,00,000 Equity Shares of Rs.10/- each.

In view of the further issue of equity shares consequent to the acquisition it is proposed to increase the authorised equity share capital from the existing limit of Rs.8,00,00,000/- divided into 80,00,000 equity shares of Rs. 10/- each to Rs. 10,50,00,000/- divided into 1,05,00,000 equity shares of Rs.10/- each.

The Resolution contained in Item No. 7 seeks to increase the Authorised Share Capital of the Company as aforesaid and to alter the Memorandum of Association and Articles of Association of the Company consequential to increase in the Authorised Share Capital of the Company. The proposal requires the consent of the members. The Board of Directors recommend that the proposal be approved.

None of the directors, key managerial personnel of the Company and their respective relatives are in any way concerned or interested, financially or otherwise, in the resolution.

ITEM NO. 8: Issue of Equity Shares

The Special Resolution as mentioned under Item No. proposes to authorize the Board of Directors to issue and allot up to 21,00,000 Equity Shares of Rs. 10 each at a price of Rs.40.00 (including premium of Rs. 30.00) or price as on relevant date, whichever is higher on SWAP Basis to the Shareholders of Decipher Software Solutions LLC.

Information pertaining to the proposed preferential allotment in terms of the Chapter VII of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 and subsequent amendments thereto is stated below:

1. Object(s) of the issue through preferential offer:

To acquire not less than 100% stake in Decipher Software Solutions LLC by way of swapping of Shares from the Shareholders of Decipher Software Solutions LLC.

Brief Profile

Decipher Software Solutions, LLC is an Information Technology services firm specializing in ERP Implementation, Mobile & Cloud solutions, Product Development and Offshore Services incorporated Outside India in Florida, USA.

The Company professionalism combined with advanced technology, best practices and industry expertise helps to deliver client's mission critical system on-time and within budget. As SAP continues to expand its solutions to include advanced analytics and big data federation as well as cloud solutions, the need for specialized resources becomes even more critical.

Decipher helps its customers to develop and implement a strategy that reaches beyond SAP to provide real solutions to business issues. From assessments, business consulting, upgrades, application development and maintenance and managed services, the skilled consultants of the company deliver insights that meet the needs of business and deliver the results and value they demand. One of the other softwares, Rightdata is an easy to use, yet powerful Data Reconciliation software that allows Data Driven Application Stakeholders to efficiently design, build, automate, maintain and collaborate on Reconciliation Processes. Rightdata's reconciliation engine powered by Hadoop makes it highly scalable and effective.

2. Number of shares and Pricing of Preferential issue:

It is proposed to issue and allot in aggregate and upto 21,00,000 Equity Shares of Rs. 10 each at a price of Rs.40.00 (including premium of Rs. 30.00) or price as on relevant date, whichever is higher on SWAP Basis to the Shareholders of Decipher Software Solutions LLC.

3. The proposal of the Promoters / Directors / Key Management Persons of the Issuer to subscribe to the offer:

None of the Promoters, Directors or Key Management Person of the Company intends to subscribe to the Offer being proposed under Special Resolution of the Notice for approval of Members at this meeting.

4. Pricing of the price:

The Equity Shares will be issued at a Price which is more than or equal to the price mentioned in the Valuation Report made by M/s. CKP Financial Services Private Limited, Merchant Bankers, in accordance with the price determined in terms of Regulation 164 / 165 of Chapter V of SEBI (ICDR) Regulations.

Accordingly, Issue Price works out to Rs. 40.00 (including premium of Rs. 30.00) per Equity Share. The SWAP Ratio has been arrived at 1050:1 i.e., 1050 Equity Shares of the Company for every one share of Decipher Software Solutions LLC swapped. This results in issuance of upto 21,00,000 Equity Shares of Rs. 10/- each by Combat Drugs Limited to the certain Equity Shareholders of Decipher Software Solutions LLC. SEBI (ICDR) Regulations, 2018 provides that the issue of shares on a preferential basis can be made at a price not less than the higher of the following:

The issue of shares on a preferential basis can be made at a price not less than the higher of the following:

a) In case of frequently traded shares:

The allotment of securities on preferential basis can be made at a price not less than higher of the following:

The average of the weekly high and low of volume weighted average prices of the related equity shares quoted on the recognized stock exchange during the twenty-six weeks preceding the relevant date;

Or

The average of the weekly high and low of the volume weighted average prices of the related equity shares quoted on a recognized stock exchange during the two weeks preceding the relevant date.

"frequently traded shares" means shares of an issuer, in which the traded turnover on any stock exchange during the twelve calendar months preceding the relevant date, is at least ten percent of the total number of shares of such class of shares of the issuer:

Provided that where the share capital of a particular class of shares of the issuer is not identical throughout such period, the weighted average number of total shares of such class of the issuer shall represent the total number of shares. "

b) In case of Infrequently traded shares:

The price determined by the issuer shall take into account valuation parameters including book value, comparable trading multiples, and such other parameters as are customary for valuation of shares of such companies:

Provided that the issuer shall submit a certificate stating that the issuer is in compliance of this regulation, obtained from an independent merchant banker or an independent chartered accountant in practice having a minimum experience of ten years, to the stock exchange where the equity shares of the issuer are listed.

"Relevant Date", SEBI (ICDR) Regulations would be 8th November, 2019, as 9th November, 2019 the date 30 days prior to the date of this AGM is a weekend day and hence 8th November, 2019 being the day preceding the weekend day, shall be considered as the Relevant Date for the purpose of above mentioned issue of Equity Shares as per Regulation 161.

5. Relevant Date:

The "Relevant Date" in accordance with SEBI (ICDR) Regulations would be 8th November, 2019, as 9th November, 2019 the date 30 days prior to the date of this AGM is a weekend day and hence 8th November, 2019 being the day preceding the weekend day, shall be considered as the Relevant Date for the purpose of above mentioned issue of Equity Shares as per Regulation 161.

6. Shareholding Pattern before and after the Preferential Issue of the capital would be as follows:

S. No	Category	Pre - Issue holding Details		Post Issue holding details	
		No. of Shares	% of shares	No. of Shares held	% of shares
A	Promoters' Shareholding:				
1	Indian Promoters	0	0.00	0	0.00
2	Foreign Promoters	4639927	58.00	4639927	45.94
	Sub Total (A)	46,39,927	58.00	46,39,927	45.94
B	Public Shareholding:				0.00
1	Institutions	300	0.00	300	0.00
2	Non-Institutions:	0	0.00	0	0.00
A.	Bodies Corporate	5,43,396	6.79	5,43,396	5.38
B.	Individuals	28,14,402	35.18	28,14,402	27.87
	NRIs	1225	0.02	2101225	20.80
	Clearing Members	750	0.01	750	0.01
C.	Any Others (HUF)	0	0.00	0	0.00
	Sub Total (B)	33,60,073	42.00	54,60,073	54.06
	Grand Total (A+B)	80,00,000	100.00	1,01,00,000	100.00

7. Proposed time within which the allotment shall be completed:

The equity shares shall be allotted within a period of 15 days from the date of passing of the Resolution by the Shareholders provided that where the allotment is pending on account of pendency of any approval from any regulatory authority including SEBI or Central Government or Reserve Bank of India the allotment shall be completed by the Company within a period of 15 days from the date of such approval.

8. Change in Management / SEBI Takeover Code:

There shall be no change in the management or control of the Company pursuant to the aforesaid issue.

9. No. of persons to whom allotment on preferential basis have already been made during the year, in terms of number of securities as well as price:

During the period from 1st April, 2019 till date of notice of this AGM, the Company has not made any preferential allotments.

10. Valuation for consideration other than cash: Swap of shares

11. The justification for the allotment proposed to be made for consideration other than cash together with valuation report of the registered valuer:

The company proposes to acquire the business of Decipher Software Solutions LLC which would enable the company to foray into software business which have very good prospects and also increase the profitability of the company. The value of Equity Shares has been arrived based on the Valuation report issued by CKP Financial Services Private Limited, Merchant Banker, dated 8th November 2019; and that the Purchase Consideration has been approved by the Board of Directors.

12. Lock-in period:

The Equity Shares being allotted pursuant to SWAP Basis to the Shareholders of Decipher Software Solutions LLC shall be subject to a lock-in for such period as specified under applicable provisions of SEBI (ICDR) Regulations. The entire preferential allotment shareholding of the above allottees shall be locked-in from the Relevant Date upto the period of 6 months if any.

13. Listing:

The Company will make an application to the Stock Exchanges at which the existing shares are already listed, for listing of the equity shares being issued on SWAP Basis to the Shareholders of Decipher Software Solutions LLC. Such Equity Shares, once allotted, shall rank paripassu with the existing equity shares of the Company in all respects, including dividend.

14. Auditors' Certificate:

The Statutory Auditor's certificate, as required under Regulation 163(2) of the Regulations will be made available for inspection at the Registered Office of the Company between 10 a.m. and 1 p.m. on all working days (excluding Saturday and Sunday) up to the date of the meeting.

15. Other Disclosures / Undertakings:

- i. It is hereby confirmed that neither the Company nor its Directors and to the Company's Knowledge any of its Promoters is a wilful defaulter.
- ii. The proposed allottees have confirmed to the Company that they have not sold / transferred any Equity Shares of the Company during the period of six months prior to the Relevant Date. The entire Shareholding of the proposed allottees in the Company if any is held by them in dematerialized Form.

In terms of SEBI (ICDR) Regulations, 2018 issuer hereby undertakes that:

- a) It shall re-compute the price of the specified securities in terms of the provision of these regulations where it is required to do so.
- b) If the amount payable on account of the recomputation of price is not paid within the time stipulated in these regulations, the specified securities shall continue to be locked-in till the time such amount is paid by the allottees.

16. Identity of Proposed Allottee (including natural persons who are the ultimate beneficial owners of equity shares proposed to be allotted and/or who ultimately control), the percentage (%) of Post Preferential Issue Capital that may be held by them and Change in Control, if any, consequent to the Preferential Issue:

The proposed allottees do not have any shares in the company as on day.

Sr. No	Name of the Proposed Allottee	Category	Pre - Shareholding		No. of shares proposed to be allotted	Post - Shareholding		Names of the Ultimate Beneficiaries/ Owners
			No of Shares	%		No of Shares	%	
1	Mr. Pavan Mantripragada PAN : BSRPM5973Q	Non - promoter	0	0	10,29,000	10,29,000	10.19	Mr. Pavan Mantripragada
2	Mrs. Janaki Yenamandra PAN : BCGPY3999B	Non - promoter	0	0	10,71,000	10,71,000	10.60	Mrs. Janaki Yenamandra
	Total		0	0	21,00,000	21,00,000	20.79	

17. Consequential Changes in the Voting Rights:

Voting Rights will change according to the change in the shareholding pattern mentioned above.

18. Approvals:

The Company will take necessary steps to obtain the required approvals from the Stock Exchange, SEBI, RBI or any other regulatory agency as may be applicable for the proposed preferential issue of Equity shares.

19. Compliances:

The Company has complied with the requirements of SEBI (Issue of Capital and Disclosures Requirements), Regulations 2015, including Regulation 38 i.e. maintaining a minimum of 25% of the paid up capital of the Company with the public.

20. Approval under the Companies Act, 2013

Section 62(1) of the Companies Act, 2013 provides, inter alia, that when it is proposed to increase the subscribed capital of a Company by further issue and allotment of shares, such shares shall be first offered to the existing shareholders of the Company in the manner laid down in Section 62 unless the shareholders decide otherwise in General Meeting /Postal Ballot by way of a SpecialResolution.

Hence, consent of the shareholders by way of a Special Resolution is being sought pursuant to Section 62(1)(c) and all other applicable provisions of Companies Act, 2013 and in terms of the provisions of the SEBI (ICDR) Regulations, 2018 and the SEBI (LODR) Regulations, 2015, issue and allot equity shares as stated in the resolution, which would result in further issuance of securities of the company to the Promoters and others on a preferential basis, in such form, manner and upon such terms and conditions as the Board may in its absolute discretion deemfit.

The Board of Directors commends the resolution as set out at Item No. 8 for approval of the shareholders as a SpecialResolution.

None of the Directors or any Key Managerial Personnel or any relative of any of the Directors/Key Managerial Personnel of the Company is, in anyway, concerned or interested in the above resolution.

ITEM NO. 9 : Disinvestment of Singapore Subsidiary

The company proposes to disinvest its entire investment of 7122 equity shares of Face Value SGD 1/- each in RA LABS PTE LTD., which is an overseas wholly owned subsidiary Company of the company to Mr. Janakiram Ajarapu. The Board keeping in view the hardship incurred as the subsidiary company has not received the expected growth, it feels that it is prudent to withdraw investment from the wholly owned Subsidiary and consider the proposed disinvestment in the best interests of the Company. Such disinvestment will amount to sale of substantial interest in undertaking by the Company, and your Directors propose resolution under section 180(1)(a) of the Companies Act, 2013 for the approval of the shareholders. The Company at the same time is in the process of identifying other viable projects and business opportunities.

Members of the Company are further requested to note that Section 180(1)(a) of the Companies Act, 2013 mandates that the Board of Directors of the company shall exercise the power to sell, lease or otherwise dispose off the whole or substantially the whole of any undertaking(s) of the company, only with the approval of the members of the Company by way of a special resolution.

The Board commends the Resolutions at Item No.9 of the accompanying Notice for approval by the Members of the Company.

None of the Directors and Key Managerial Personnel of the Company or their relatives are concerned or interested in the passing of the Resolution at Item No 9 of the accompanying Notice except to the extent of their shareholding in the company.

By the Order of the Board
For **COMBAT DRUGS LIMITED**
Sd/-

SUSHANT MOHAN LAL
DIRECTOR

Place: Hyderabad
Date: 08.11.2019

DIRECTORS' REPORT

Dear Members,

Your Directors take pleasure in presenting you the **Thirty Third Annual Report** of the Company together with the Audited Statements of Accounts for the financial year ended 31st March, 2019.

FINANCIAL RESULTS

The Company's financials for the year under review along with the corresponding figures of the previous year's figures are as under:-.

(Amount in Lakhs)

	For the year ended	
	31-03-2019	31-03-2018
Net Income from		
Sales & Other Operations	678.70	113.00
Profit before Depreciation	37.69	18.24
Less Depreciation	-	-
Net Profit/(Loss) after Interest and Tax	37.69	18.24
Balance carried to Balance Sheet	37.69	18.24
Earnings per share	0.47	0.23

DIVIDEND

No dividend has been recommended by the Board of Directors for the financial year 2018-19. Since the company has not declared any dividend for more than 10 years the provisions of Section 125 (2) of the Companies Act, 2013 do not apply.

RESERVES

There were no transfers to Reserves during the financial year 2018-19.

Standalone and Consolidated Financial Statements :

The Standalone and Consolidated Financial Statements of your Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015, as amended. Further, a statement containing the salient features of the Financial Statements of our subsidiaries pursuant to subsection 3 of Section 129 of the Companies Act, 2013 in the prescribed form AOC-1 is appended as Annexure 1 to the Board's Report. The Statement also provides the details of performance and financial position of each of the subsidiaries.

REVIEW OF BUSINESS OPERATIONS AND FUTURE PROSPECTS -State of Affairs :

The highlights of your Company's Standalone performance are as under:

- Revenue from operations for FY19 stood at Rs. 678.99 Lakhs compared to Rs. 113 Lakhs for FY18. Other income for FY19 amounting to 0.88 Lakhs compared to Rs. 11.37 Lakhs for FY18, primarily comprised income from Pharma & I.T business.
- The company is maintaining healthy Core operating margins (EBIDTA margins).
- The Company is getting their products of WHO GMP standards manufactured on Third Party manufacturing basis with a reputed company/s. The company is very confident of building decent business volumes in due course of time.

SUBSIDIARIES:

Your Company has formulated a policy for determining 'material' subsidiaries pursuant to the provisions of SEBI LODR.

During FY19, ICP Solutions Private Limited, Hyderabad, the wholly owned subsidiary of Combat Drugs Limited started its operations and during the three Months of operations it achieved a Net turnover of Rs.126.99 Lakhs contributing to the overall positive health of the company.

- The wholly owned subsidiary of Combat Drugs Limited, R.A. Labs Pte Ltd, Singapore is yet to commence commercial operations. As the envisaged purpose is not being met through the incorporation of the Subsidiary, the company is contemplating the sale of the Singapore Subsidiary and has asked for Shareholder approval in this Annual General Meeting.
- As on March 31, 2019, your Company has 2 subsidiaries. A report on the performance and financial position of each of the subsidiaries are presented below.

All Amount except EPS in Rs. Lakhs Unless Specified

	ICP SOLUTIONS PVT LTD		RA LABS PTE LTD	
	31/03/19	31/03/18	31/03/19	31/03/18
Net Income from Sales & Other Operations	126.99	-	0.68	-
Profit before Depreciation	11.03	-	(4.65)	-
Less: Depreciation	-	-	-	-
Net Profit/(Loss) after Interest and Tax	7.51	-	(4.65)	-
Balance carried to Balance Sheet	7.51	-	(4.65)	-
Earnings per share	75.06	-	(6.533)	-

The company to accelerate its growth module has identified a target company in USA which is operating in the field of Information Technology Services specializing in Pharma sector as well as ERP Solutions, Business Intelligence, Data Warehousing, Software Development, Consulting, Programming and Offshore Development, having an Income Revenue of USD \$11.86 Million (approx Rs.81.83 Crores at Rs.69.00 per US dollar) and a Gross Profit of USD \$0.773 Million (approx Rs.5.33 Crores at Rs.69.00 per US dollar) as of their Financial Year ended 31st December, 2018. The Target company has clients in Healthcare, Hospitality, Financial services etc ranging from small businesses to Fortune 1000 companies including clients such as Merck, Allregan, Bank of America, SAP, IBM, among others. The Board with a view of making the company's global presence in the field of Pharma and Information Technology, is considering the proposal of the acquisition of the target company, subject to Due Diligence of the Target company and its authorized representatives and the Feasibility and Viability report.

ACQUISITION OF “DECIPHER SOFTWARE SOLUTIONS LLC (DSSL)“

Your directors have been in discussions with the promoters of DSSL for acquisition of the same. M/S DSSL is located in Florida, USA and is engaged in the Business of Information Technology since 2007. The present turnover for the financial year ended 31st December, 2018 was Rs. 81.83 Crores and the Profit was Rs. 5.53 Crores (at 69.00 per USD). Your Directors expect that this acquisition would be beneficial to the company in terms of business and profitability.

FURTHER ISSUE OF SHARES

If the acquisition fructifies, your Directors propose to issue and allot further shares for consideration other than cash i.e., in lieu of the consideration to be paid against the shares to be acquired from the promoters of Decipher Software Solutions LLC. The details of the shares to be issued are given in the notice convening the Annual General Meeting for approval of the shareholders.

CHANGE IN THE BUSINESS OF THE COMPANY

During the year under review, the company did not change its line of activity.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

In terms of the provisions of Regulation 34 of the SEBI LODR, the Management's discussion and analysis is set out in this Annual Report

CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION

As per Regulation 27(2) of SEBI (Listing Obligations and Disclosure Requirements), 2015, provisions relating to corporate governance are not applicable to the company. However, your Company has taken adequate steps to adhere to all the stipulations laid down under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, your Company is committed to maintain the highest standards of corporate governance as we

believe that it is critical to enhance and retain investor trust. We have practiced several best corporate governance practices in the Company to enhance long-term shareholder value and respect minority rights in all our business decisions. A report on Corporate Governance is included as part of this Annual Report as “Annexure – B”.

LISTING & TRADING ON STOCK EXCHANGES

The Equity Shares of the Company are listed on The Bombay Stock Exchange Limited, Mumbai. The Market price of the Share as on 31st March, 2019 was Rs. 26.20 as compared to Rs. 20.20 per share on even date of 2018. The Company confirms that it has paid the Annual Listing Fee for the year 2018-19 to BSE.

SHARE CAPITAL

As on 31st March, 2019	Authorised	Issued Subscribe & Paid-up
No. of Equity Shares	80,00,000	80,00,000
Face Value	10.00	10.00
Share Capital in Rs.	8,00,00,000	8,00,00,000

During the period under review, there was no increase in share capital of the Company. The Company has not issued any shares with differential rights and hence no information as per provisions of Section 43(a)(ii) of the Act read with Rule 4(4) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.

It was proposed to increase the Authorised Capital of the company from Rupees Eight Crores, divided into Eighty Lakh Shares of Rupees Ten Each at par to Rupees Ten Crore Ten Lakhs divided into One Crore One Lakh Equity Shares of Rupees Ten Each at Par. However, the same has been deferred to the current year and hence the approval of the shareholders is sought for the same.

DEMATERIALISATION OF SHARES

90.13% of the company’s paid up Equity Share Capital is in dematerialized form as on 31st March, 2019 and balance 9.87% is in physical form as of 31st March, 2019.

The Company’s Registrars are M/s Venture Capital & Corporate Services Private Limited, 12-10-167, Bharat Nagar, Hyderabad-500 018, Telangana. Phone: (+91)-4023818475/476 FAX: +91 40 23868024 Email id: info@vccipl.com.

The shareholders who continue to hold shares of the company in physical form will not be able to lodge the shares with company / its RTA for transfer. They will need to convert them to demat form compulsorily if they wish to effect any transfer. Only the requests for transmission and transposition of securities in physical form will be accepted by the company / their RTAs.

All the investors who are holding shares in physical form, should consider opening a demat account at the earliest and submit request for dematerialization of their shares in order to protect the liquidity of the shares.

BOARD EVALUATION

The Board of Directors has carried out an annual evaluation of its own performance, Board committees and individual directors pursuant to the provisions of the Act and the corporate governance requirements as prescribed by SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”).

The performance of the Board was evaluated by the Board after seeking inputs from all the directors on the basis of the criteria such as the Board composition and structure, effectiveness of board processes, information and functioning, etc.

The Board and the Nomination and Remuneration Committee (“NRC”) reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the Board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. The performance evaluation of the Independent Directors was carried out by the entire Board. The performance evaluation of the Chairperson and Managing Director was carried out by the Independent Directors.

In a separate meeting of independent Directors, performance of non independent directors, performance of the board as a whole and performance of the Board was evaluated, taking into account the views of executive directors and non-executive directors. The same was discussed in the board meeting that followed the meeting of the independent Directors, at which the performance of the Board, its committees and individual directors was also discussed.

MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

- (a) There are no other Material Changes and Commitments affecting the financial position of the Company which occurred between the end of the financial year to which the financial statements relate and the date of this Report.

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY’S OPERATIONS IN FUTURE

There is no order passed by any Court or Tribunal or forum which impacted or is likely to impact the “Going concern status” of the company.

DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS

The company has adequate internal financial controls and has a separate Audit committee to assess the internal controls and guide the company accordingly.

DETAILS OF SUBSIDIARIES, JOINT VENTURES, ASSOCIATE COMPANIES & THEIR PERFORMANCE

The Company has a Subsidiary Company in Singapore in the name & style of RA LABS Pte Ltd. The operations of the Subsidiary are limited to being a holding company and does not have an impact on the performance of the parent company. The Board is now contemplating the Sale of this Subsidiary as the purpose for which it was opened is now redundant.

The Company had opened a Subsidiary Company in Hyderabad, Telangana, India in the month of May, 2018, in the name and style of ICP Solutions Private Limited to expand the business of the company in Information Technology internationally.

The company started its operations in the Month of December 2019 and has achieved a turnover of 126.99 Lakhs with a profit of 11.03 Lakhs in the short period of operations. The company is further developing on all fronts.

DEPOSITS

The Company has not accepted any Public Deposits during the year under review.

STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY

The Company has a Risk Management Policy. However, the elements of risk threatening the Company's existence are very minimal.

DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES

The provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility does not apply to the company.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013

There were no loans, guarantees or investments made by the Company under Section 186 of the Companies Act, 2013 during the year under review and hence the said provision is not applicable.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

There was no contract or arrangements made with related parties as defined under Section 188 of the Companies Act, 2013 during the year under review except with the subsidiary/s of the company.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirement of Section 134 of the Companies Act, 2013, the Board of Directors of the Company make the following statements, to the best of their knowledge and belief and according to the information and explanations obtained by them:

- a) That in the preparation of the annual financial statements for the year ended March 31, 2019, the applicable accounting standards (IND AS) have been followed and there have been no material departures there from;
- b) That the accounting policies mentioned in notes to the Financials Statements have been selected and applied consistently and judgments and estimates have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2019 and of the profits of the Company for the year ended on that date;
- c) That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) That the annual financial statements have been prepared on a going concern basis;
- e) That proper internal financial control has been laid down to be followed by the Company and such internal financial controls are adequate and operating effectively.
- f) That proper systems are in place to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND THE PRACTICING COMPANY SECRETARY IN THEIR REPORTS

Statutory Auditors M/s Anandam & Co, Chartered Accountants (ICAI Registration No. 000125S) were appointed as the Statutory Auditors of the Company to hold office from the conclusion of the 32nd AGM held on September 29, 2018 until the

conclusion of the 33rd AGM of the Company to be held in the calendar year 2019. The Auditors' Report on the financial statements of the Company for the year ending March 31, 2019 is unmodified i.e. it does not contain any qualification, reservation or adverse remark. The Auditors' Report is enclosed with the financial statements forming part of the Annual Report.

COST AUDITORS AND THEIR REPORT

The provisions of Section 148 of the Companies Act 2013 does not apply to the company and hence no cost auditor is appointed.

Secretarial Standards The Company complies with all applicable mandatory secretarial standard issued by the Institute of Company Secretaries of India

Secretarial Auditors Pursuant to the provisions of Section 204 of the Companies Act, 2013 and rules thereunder, M/s Marthi & Co., Company Secretaries were appointed to conduct the secretarial audit of the Company for the FY 2018-19. The Secretarial Audit Report for FY 2018-19 is appended herewith to the Board's Report.

There were no qualifications, reservations or adverse remarks made by either the Auditors or by the Practicing Company Secretary in their respective reports

COMPANY'S POLICY RELATING TO KEY MANAGERIAL & DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES

The Nomination & Remuneration Committee is vested with the powers to recommend the Appointment of a Director and Key Managerial Personnel to fix and recommend the Remuneration accordingly.

Managerial Remuneration

A) Details of the ratio of the remuneration of each director to the median employee's remuneration and other details as required pursuant to Rule 5 (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are as under:

Name	Designation	Yearly Remuneration (Rs).
1. Mr.Sushant Mohan Lal	ExecutiveDirector	9,00,000.00
2. Mr. Vasudev K	Whole Time Director	NIL
3. Mr. Raghuram	Independent Director	NIL
4. Smt. Vemuri Shilpa	Independent Director	NIL

B) Details of every employee of the Company as required pursuant to 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 :

1. The Ratio as such is not applicable.

- C) Any director who is in receipt of any commission from the company and who is a Managing Director or Whole-time Director of the Company shall receive any remuneration or commission from any Holding Company or Subsidiary Company of such Company subject to its disclosure by the Company in the Board's Report — NIL

ANNUAL RETURN

The extracts of the Annual Return pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and administration) Rules, 2014 in Form MGT 9 is attached to this Report at Annexure.

BOARD MEETINGS

The Board during the financial year 2018-19 met Ten times. Detailed information regarding the meetings of the Board are included in the report on Corporate Governance, which forms part of the Board's Report.

The Company constituted 3 Committees as under:

- (I) Audit Committee;
- (II) Nomination & Remuneration Committee ;
- (III) Share holders Grievance Relationship/Share Transfer Committee

The details are given as Annexure in the Corporate Governance Report.

DIRECTORS

The Board as a main functionary is primarily responsible to ensure value creation for its stake holders. The Board of Directors and its committees through their leadership and guidance ensures the highest standards of corporate governance. There were 4 Directors on the Board of the Company as at 31st March 2019. There is an appropriate combination of Independent & Non-Independent Directors on Board of the Company.

CHANGES IN DIRECTORS AND KEY MANEGERIAL PERSONEL

In accordance with the provisions of the Companies Act, 2013,

Sri. Vasudev Kommaraju, was appointed as Whole Time Director with effect from 27th March, 2019.

Mr. Kumar Raghavan was appointed as Company Secretary and Comliance Officer of the company.

Mrs. Sonam Jalan was appointed as Chief Financial Officer of the company with effect from 27th March, 2019.

COMPLIANCE OFFICER:

Mr. Kumar Raghavan is the Compliance Officer of the Company.

DECLARATION BY INDEPENDENT DIRECTORS

The company has received necessary declarations from all the independent directors of the Company that they meet the criteria of independence as provided in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (LODR) Regulations, 2015.

DISCLOSURE OF COMPOSITION OF AUDIT COMMITTEE AND PROVIDING VIGIL MECHANISM

The Audit Committee consists of the following members:

- i) Shri Ragu Raghuram
- ii) Smt Vemuri Shilpa
- iii) Shri. SushantMohan Lal

The above composition of the Audit Committee consists of independent Directors viz.,Shri Ragu Raghuram and Smt Vemuri Shilpa, who form the majority.

The Audit Committee reports to the Board. The Company has a vigil mechanism in place.

RISK MANAGEMENT:

The company has formulated & adopted a Risk management policy at its board Meeting. As per the policy, the management continues to review and assess the Risk and also take steps for mitigating the same.

CORPORATE SOCIAL RESPONSIBILITY:

The provisions of the Companies Act, 2013 and rules made there under ("the Act"), forming of a Corporate Social Responsibility (CSR) Committee is Not Applicable to the Company.

Transfer of Amounts to Investor Education and Protection Fund

Your Company did not have any funds lying unpaid or unclaimed for a period of seven years. Therefore there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

OBLIGATION OF COMPANY UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013.

During the year 2018-19, No. of complaints received & disposed off were - NIL -

PARTICULARS OF EMPLOYEES:

Information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is given elsewhere in the report. As per the proviso to Rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the particulars of employees posted and working outside India is - NIL.

Extract of Annual Return In accordance with the provisions of Section 134(3)(a) and 92(3) of the Companies Act, 2013, an extract of the annual return in the prescribed format is appended herewith as Annexure to the Board's Report.

Details of Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outflow [Clause (m) of sub-section (3) of section 134 of the Act, r/w Rule 8 of the Companies (Accounts) Rules, 2014]

(A) Conservation of energy

The Company is getting their Products manufactured on Third Party Manufacturing basis & hence the energy consumed for manufacturing activities during the year was NIL & hence, no additional Investments or proposals were implemented for reduction of consumption of energy.

(B) Technology absorption: The Company did not carry out any R & D during the year under review.

(C) Foreign exchange earnings and Outgo:

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows is as follows:

Foreign Exchange Inflows: Rs. 41.25 Lakhs

Foreign Exchange Outflows: Rs. 2.22 Lakhs

ACKNOWLEDGEMENTS

Your Directors place on record their sincere thanks to Bankers, Business Associates, Consultants, and various Government Authorities for their continued support extended to your company's activities during the year under review. Your Directors also acknowledge gratefully the shareholders for their support and confidence reposed on your Company.

For and on behalf of the Board
For COMBAT DRUGS LIMITED

Place: Hyderabad
Date: 08.11.2019

Sd/-
VASUDEV KOMMARAJU
DIRECTOR

Sd/-
SUSHANT MOHANLAL
DIRECTOR

DETAILS OF UNCLAIMED SHARES

The Company is required to open an unclaimed suspense account with a depository participant and transfer all the unclaimed share certificates of members after giving three reminders.

All the voting rights on unclaimed shares shall remain frozen till the rightful owner of such shares claims the shares.

As on March 31, 2019 your Company has no equity shares in the unclaimed suspense account.

S.No.	Particulars	Remarks
1.	Total number of shareholders and the outstanding shares in the suspense account lying as on 31.03.2019	Nil
2.	Number of shareholders who approached listed entity for transfer of shares from suspense account during the year;	Nil
3.	Number of shareholders to whom shares were transferred from suspense account during the year;	Nil
4.	Aggregate number of shareholders and the outstanding shares in the suspense account lying as on 31.03.2019	Nil

Green Initiative for Paperless Communications

The Ministry of Corporate Affairs (“MCA”) has taken a “Green Initiative in Corporate Governance” by allowing paperless compliances by Companies through electronic mode. In accordance with the recent circular bearing no.17/2011 and 18/2011 dated April 21, 2011 and April 29, 2011 issued by the Ministry of Corporate Affairs, Companies can now send various notices/documents to their shareholders through electronic mode to the registered e-mail addresses of the shareholders. This is a golden opportunity for every shareholder of the Company to contribute to the Corporate Social Responsibility initiative. This move by the Ministry is a welcome move, since it will benefit the society at large through reduction in paper consumption and contribution towards a greener environment. Additionally, it will avoid loss in postal transit, save time, energy and costs.

Pursuant to the said circular, the company has forwarded e-mail communication to all share holders whose email id were registered in the Depository records that the company intends to use the said e-mail id to send various Notices/Correspondences etc .

By Understanding the underlying theme of the above circulars, to support this green initiative of the Government in full measure, the company is sending the documents like notice convening general meetings, financial statements, directors

reports, auditor's report etc to the email address registered with the depositories by the shareholders holding shares in electronic form and for shareholders holding shares in physical form, the physical copy to the address registered with the Registrar and Share transfer Agents of the Company.

In this regard, we request shareholders who have not registered their email addresses, so far to register their email addresses, in respect of electronic holding with depository through their concerned depository participants and Members who hold shares in physical form are requested to send the required details to the Registrar and Share Transfer Agent, M/s Venture Capital & Corporate Services Private Limited, 12-10-167, Bharat Nagar, Hyderabad-500 018, Telangana. Phone: (+91)-4023818475/476 FAX: +91 40 23868024 Email id: info@vccipl.com.

Depository Services:

For guidance on depository services, Shareholders may write to the Company / Venture Capital or to the respective Depositories:

National Securities Depository Ltd.

Trade World, 4th Floor, Kamala Mills Compound,
Senapati Bapat Marg, Lower Parel, Mumbai-400 013.
Tel : 091-022-24994200,
Fax:091-022-4972993/24976351
Email : info@nsdl.co.in

Central Depository Services (India) Ltd.

A-Wing, 25th Floor, N.M. Joshi Marg,
Lower Parel, Mumbai – 400 013.
Tel : 091-022-22723333,
Fax : 091-022-22723199
Email: investors@cdslindia.com

Annexure - II

**Statement of particulars as per Rule 5 of Companies
(Appointment and Remuneration of Managerial personnel)
Rules, 2014.**

- (i) The ratio of the remuneration of each director to the median remuneration of the employees of the company for the financial year:

S.No.	Name of the Director	Ratio of the remuneration of the median remuneration of the employees
1.	Mr.Sushant Mohan Lal	NA
2.	Mr. Vasudev Kommaraju	NA
3.	Smt. Vemuri Shilpa	NA
4.	Mr. Ragu Raghuram	NA
5.	Mr. Kumar Raghavan	NA
6.	Smt. Sonam Jalan	NA

- (ii) The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager in the financial year.

S.No.	Name of the KMP	% increase in remuneration
1.	Mr. Sushant Mohan Lal	NA
2.	Mr. Kumar Raghavan	NA
3.	Smt. Sonam Jalan	NA

For and on behalf of the Board
For COMBAT DRUGS LIMITED

Place: Hyderabad
Date: 08.11.2019

Sd/-
VASUDEV KOMMARAJU
DIRECTOR

Sd/-
SUSHANT MOHANLAL
DIRECTOR

PART-B

Information under Section 197 (12) of the Companies Act, 2013 read with the rule 5(2) Companies (Appointment and remuneration of managerial personnel) Rules, 2014 and forming part of Directors Report for the year ended March 31, 2019

Names of top 10 Employees Employed throughout the Financial Year and in receipt of remuneration aggregating Rs 1,00,00,000 (1 Crore) or more

Name of the Employee	Designation	Remuneration (in Rs.)	Qualification	Experience (Years)	Date of Commencement of Employment	Age	Last employment held before joining the Company	% of equity company shares held in the Company
NIL								

Names of top 10 Employees Employed throughout the Financial Year and in receipt of remuneration for a part of that year, at a rate which, in the aggregate, was not less than 8,50,000 lakh rupees Per Month

Name of the Employee	Designation	Remuneration (in Rs.)	Qualification	Experience (Years)	Date of Commencement of Employment	Age	Last employment held before joining the Company	% of equity company shares held in the Company
NIL								

- (iii) Employee employed throughout the financial year or the part thereof, was in receipt of remuneration in that year which, in the aggregate, or the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than 2 % of the equity shares of the company: Nil

For and on behalf of the Board
For COMBAT DRUGS LIMITED

Place: Hyderabad
Date: 08.11.2019

Sd/-
VASUDEV KOMMARAJU
DIRECTOR

Sd/-
SUSHANT MOHANLAL
DIRECTOR

MANAGEMENT DISCUSSION & ANALYSIS

GLOBAL PHARMACEUTICAL MARKET & INDUSTRY REVIEW

As per the International Monetary Fund, global economic growth remained steady in 2018, with a projected annual growth rate of 3.7%. This was despite concerns over international trade, weaker economic performance in some countries, notably Europe and Asia, and geopolitical friction. Economic growth, an expanding global population and technological change are expected to contribute to growth in the pharmaceutical industry. However, social, economic and political challenges remain in meeting unmet medical needs. The global healthcare market continues to grow, despite signs of economic slowdown in some countries.

Growth is expected to be driven by the continued uptake and anticipated launch of novel therapies, including gene and cell therapy addressing key unmet needs, as well as increasing access to medicines globally. Payer scrutiny and sales losses from genericization and biosimilar competition will act as brakes on growth.

Trends Impacting the Global Pharmaceutical Sector

- Growing and ageing populations, Advances in Science & Technology and Key R&D Focus Areas, Pricing and Access, and Regulatory Environment & Geopolitical Uncertainties are key factors impacting the global Pharmaceutical Sector.

Demographic change is driving demand for both preventive and therapeutic healthcare products. The world's population is rising and more people are living longer. An ageing population and changing Life styles in society are contributing to steady increases in non-communicable diseases (NCDs). These diseases include cancer and cardiovascular, metabolic and respiratory diseases often associated with lifestyle choices, including smoking, diet and lack of exercise. NCDs are also associated with ageing and, with the world having higher number of older people (over 65 years of age), healthcare costs are rising as people are living longer. Rapid advances made in the area of scientific advancement are transforming development of newer medical therapies.

The Pharmaceutical drugs sector is expected to outperform the market, almost doubling in size over 2018-2024 and peaking at US\$262bn in 2024, accounting for approximately 20% of prescription sales. This highlights the industry's continued move to address small groups of neglected patients with high unmet needs and to benefit from regulatory and financial incentives.

INDIANPLAYERS IN GLOBAL MARKETS:

The country's share in global generics exports stands at 20% and it is the largest maker of generics drugs globally & is expected to hold its dominance in the Generics market.

Combat Drugs Limited is striving to:

1. Acquire niche, low competition and high-tech barrier/complex products.
2. Joint venture(s) to develop generic products and bring to US market in a short period of time.

The Company is concentrating on new products with very high scope and are also in the process of Finalizing Joint Ventures while contemplating takeovers of Pharma companies in USA. The proposed acquisition of the IT Company in USA, which caters to various healthcare companies apart from other clients, is a stepping stone towards the overall goal of having the global reach by the Company.

Opportunities and Threats

The key challenges for the Indian pharmaceutical industry include the following:

- Ensuring compliances with global CGMP standards; thereby involving continuous improvement in systems and processes including training of the workforce
- The main outlook, concerns challenges and Threats for the pharmaceutical sector in the coming years will be, decline in the margins because of increasing competition from smaller new entrants, Generic medicine pricing & policies of various Governments.

Risks and concerns

Combat Drugs Limited does a regular and stringent monitoring of its business activities to identify, evaluate and resolve risks. The top management of the Company and the Board are involved in monitoring of risk assessment and mitigation, thus ensuring a quick resolution mechanism.

In line with our stated philosophy and strategy, the company will continue to pursue various options to achieve growth while trying to reduce the cost and focus more on marketing tie-ups to expand its market reach.

Your Company has adequate internal control systems commensurate with the size of its operations for the purpose of exercising adequate controls on day to day operations of the Company and is at present involved in sourcing the products through third party manufacturing and procurement basis in GMP Manufacturing units in various locales.

The details of the financial performance of the Company are comprised in the Balance Sheet, Profit and Loss Account and other financial statements which are annexed hereto along with the Directors and the Auditors Report for the financial year 2018-19.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has a internal control framework, which is designed to safeguard its assets against loss from unauthorized use and ensure reliability of financial reporting. The management is committed to ensure an effective internal control environment, commensurate with the size and complexity of the business, which provides an assurance on compliance with internal policies.

HUMAN RESOURCES

The company is in the process of expansion of its operations and with time will need to expand the man power which had previously come down during consolidation. There is a conscious effort by the Company to build diversity in the workforce. The company through its subsidiary has sufficient manpower.

OUTLOOK

FY19 witnessed a robust growth in revenues led by Pharma & I.T Business. We expect the growth momentum across our business segments to continue in FY20 especially driven by Joint Ventures and Takeovers in USA. We expect to sustain the healthy core EBITDA margins witnessed in FY19 and also strive to wipe off the Losses in the company and bring the company back in the Green in the coming years. We intend to complete the organizational structuring and strengthening of Businesses and the human resources required to fully operationalize our I.T Division in the coming years.

Disclaimer

Some of the statements in this Management Discussion & Analysis, describing the Company's objectives, projections, estimates and expectations may be "forward looking statement" within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operation including changes in the industry structure, significant changes in political and economic environment in India, tax laws, import duties, litigation and labour relations. The Company does not undertake endeavors to update these statements.

CORPORATE GOVERNANCE REPORT

As per Regulation 27(2) of SEBI (Listing Obligations and Disclosure Requirements), 2015, provisions relating to corporate governance are not applicable to the company. However, your Company has taken adequate steps to adhere to all the stipulations laid down under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In accordance with regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the report containing the details of Corporate Governance systems and processes at Combat Drugs Limited are as follows:

Company’s philosophy on Code of Governance:

“Combat” or “the Company” believes that good Corporate Governance emerges from the application of the best management practices and compliance with the law coupled with the highest standards of integrity, transparency, accountability and ethics in all business matters. Combat also believes that sound corporate governance is critical to enhance and retain investor trust. Hence Combat’s business policies are based on ethical conduct, health, safety and a commitment to building long term sustainable relationships with relevant stakeholders.

The Company is continuously making efforts for improving the Corporate Governance practices in the company which can contribute substantially in achieving good governance and thus resulting in enhancement of value to its stakeholders, customers, employees, Banks, Government Agencies, etc.

1. Company’s Philosophy on Code of Corporate Governance

It is the Company’s endeavor to attain highest level of governance In the conduct of your Company’s business and its dealings and hence ensures adherence and enforcement of the principles of corporate governance with a focus on transparency, professionalism, fairness and accountability.

2. Board of Directors

Your Company had a balanced mix of Executive and Non-Executive Directors during the year. The composition of the Board is broadened to represent a blend of professionals from various backgrounds.

The Company is committed to maintain the highest standards of Corporate Governance and adhere to the Corporate Governance requirements set out by SEBI. The Company’s day to day affairs are managed by a competent management team under the overall supervision of the Board.

Composition of the Board : The Composition of the Board of your Company is in conformity with the SEBI LODR. The names and categories of Directors, the number of Directorships and committee positions held by them are given below.

(a) Composition and Category of Directors

The Board of Directors had an optimum combination of Two Executive and Two Non- Executive Directors one of them being a lady Director and not less than fifty percent of the Board members are Non-Executive and Independent Directors.

Executive Directors	Age	Designation	Date of Appointment
Mr. Sushant Mohan Lal	39	Director	19th May, 2006
Mr. Vasudev Kommaraju	66	Director	27th Mar, 2019

Non-Executive/or Independent Directors

Mrs. Vemuri Shilpa	31	Independent Director	30thMar, 2015
Mr. Ragu Raghuram	67	Independent Director	30thMar, 2017

NOTES:

- (1) None of the Directors are related to each other;
- (2) Number of Directorships held in other companies includes all companies, whether listed or unlisted and excludes foreign companies, other bodies corporate and professional bodies. The limits on directorship of Independent Directors and Executive Directors are within the permissible limits.
- (3) The necessary disclosures regarding change in Committee positions, if any, have been made by all the Directors, during the year under review. None of the Director is a Member of more than 10 Committees or Chairman of more than 5 Committees across all Indian companies.
- (4) Independent Director means a Non-Executive Director, who fulfils the criteria as laid down in SEBI (Listing Obligations and Disclosure Requirements) 2015
- (5) The Company has issued a formal letter of appointment to its Independent Directors. The maximum tenure of Independent Directors is in accordance with the Companies Act, 2013.
- (6) The Independent Directors of the Company met every time a Board Meeting is held. These meetings are held the same day as that of the Board Meetings. In the said meetings the Independent Directors review the matters stated in SEBI (Listing Obligations and Disclosure Requirements) 2015) and action items, if any, are communicated and tracked to closure to the satisfaction of Independent Directors.

The Company's Independent Directors meet at least once in every financial year without the presence of Executive Directors or management personnel. Such meetings are conducted informally.

Meetings

The calendar of Board meetings is decided in consultation with the Board and the schedule of such meetings is communicated to all Directors well in advance. Generally, the Board Meetings are held in Hyderabad area, where the Corporate office / Registered Office of your Company is situated.

During the year under review, your Board met 10 times during the financial year. The Board meetings were held on 04.04.2018, 30.05.2018, 23.07.2018, 22.08.2018, 05.10.2018, 14.11.2018, 20.12.2018, 02.01.2019, 14.02.2019, 27.03.2019.

The necessary quorum was present for all the Board Meetings and the Thirty Second Annual General Meeting. The intervening gap between the Meetings was not more than 120 days as prescribed under the Companies Act, 2013.

After each Board Meeting, your Company has a well-articulated system of follow up, review and reporting on actions taken by the Management on the decisions of the Board and Committees of the Board.

(b) Attendance of the Directors at the Board Meetings and the Thirty Second AGM & Shareholding of Directors as on 31st March, 2019.

No	Name	Category	No. of BM Attended	Attendance at Previous AGM	No. of Memberships (other Co's)	Shares Held	%
1	Sushant Mohan Lal	Director	10	Yes	Nil	6,55,200	8.19
2	Vasudev Kommaraju	Director	10	Yes	Nil	Nil	0.00
3	Vemuri Shilpa	Indp. Dir	10	Yes	Nil	Nil	0.00
4	Ragu Raghuram	Indp. Dir	10	Yes	Nil	Nil	0.00

All changes being additions and deletions are communicated by the Board Members and recorded in the statutory registers and applicable disclosures also made to the Stock Exchanges.

The Board has constituted the following Committees and each Committee has their terms of reference as a Charter.

- (I) **Audit Committee;**
- (II) Nomination & Remuneration Committee
- (III) Share holders Grievance /Relationship/Share Transfer Committee

I. THE AUDIT COMMITTEE

The Audit Committee was constituted in accordance with the requirements of the Listing Agreement and reports to the Board and is primarily responsible for:

- To review the internal control systems
 - To review Quarterly and Half-yearly results
 - To review the accounting and financial policies and practices
 - To review reports furnished by the internal and statutory auditors, and ensure that suitable follow-up action is taken.
- l) The Audit Committee consists of Three Directors, as per the details given below. All Members are financially literate and have the required accounting and financial management expertise.

The Audit Committee met 8 times during the financial year 2018-19. 5th April, 2018, 30th May, 2018, 23rd July, 2018, 22nd August, 2018, 14th November, 2018, 20th December, 2018, 14th February, 2019, 27th March, 2019. The necessary quorum was present for all the said Audit Committee Meetings.

The following are the members of the Audit Committee:

S.No	Name of the Director	Designation	Category
1.	Mrs. Vemuri Shilpa	Chairman	Independent, Non-Executive
2.	Mr.Raghu Raghuram	Member	Independent, Non-Executive
3.	Mr.Sushant Mohan Lal	Member	Executive

No sitting fees was paid to them for attending the meetings of the Board and or its Committees.

II. COMPANY'S POLICY RELATING TO DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES

THE NOMINATION AND REMUNERATION COMMITTEE

1. The Nomination and Remuneration Committee is primarily responsible to identify potential candidates to become Board Members besides recommending nominees to various Committees of the Board while ensuring that appropriate procedures are in place to assess Board's effectiveness.
2. Developing an annual evaluation process of the Board and its Committees.
3. Devising a policy on Board diversity;
4. Assist the Board in ensuring that affordable, fair and effective compensation philosophy and policies are implemented;
5. Approve and make recommendations to the Board in respect of salary structure and actual compensation (inclusive of performance based incentives and benefits) of the Executive Directors, including the Chief Executive Officer;

6. Review and approve the overall budgetary increment proposals, disclosures in the annual report or elsewhere besides any other matter referred to the Remuneration Committee by the Board of Directors of the Company.
 7. Nomination and Remuneration Committee - salary, benefits, perquisites and allowances (fixed component) and performance incentives, commission (variable component) to its Chairman, Managing Director and other Executive Directors.
- a. The Nomination & Remuneration Committee is vested with the powers to recommend the Appointment of a Director and fix, recommend the Remuneration accordingly.

The Nomination and Remuneration Committee comprises of the following members

S. No	Name of the Director	Designation	Category	No. Meeting Attended
1.	Mr. Ragu Raghuram	Chairman	Independent, Non-Executive	6
2.	Vemuri Shilpa	Member	Independent, Non-Executive	6
3.	Sushant Mohan Lal	Member	Director	6

The Committee held 6 (Six) meetings during the year ended March 31st, 2019.

No sitting fee or out of pocket expenses was paid to any of the Directors during the year in view of the financial constraints and performance of the company. The Comparative Ratios are– Not applicable

III. SHAREHOLDERS' RELATIONSHIP / INVESTOR GRIEVANCE/ SHARE TRANSFER COMMITTEE

In compliance with the provisions of Section 178 of the Companies Act, 2013 and the SEBI (LODR) Regulations, 2015, the Board has constituted the committee as the "Shareholders' Relationship / Investor Grievance/ Share Transfer Committee "

The Committee reviews the following: Expeditious redressal of investor's grievances, Transfer of shares, Dematerialisation/ Re-materialisation, Non receipt of Annual Reports and declared dividend, all other matters related to shareholders' Grievances & to ensure quicker investor services and expeditious disposal of the share transfer approvals. The Committee meets as and when the memorandum of transfers date is intimated by the Share Transfer Agents; VENTURE CAPITAL & CORPORATE SERVICES PRIVATE LIMITED (Registrars and Transfer Agents) and accords its approvals accordingly.

The Share Transfer Committee Met 9 times during the financial year 2018-19.

S.No	Name	category	Position held	No. of Meetings Attended
1	Sushant Mohan Lal	Director	Member	9
2	Vemuri Shilpa	Indp. Director	Chairman	9
3	Vasudev Kommaraju	Director	Member	9

All the Share Transfers were effected on time and there is no share transfer pending for more than 15 days and there are No pending Share Transfers as on 31st March 2019. During the year 2018-2019, complaints were received and resolved and as on 31st March, 2019 there were no complaints pending to be resolved.

No sitting fees was paid to them for attending any meeting of the Board and or its Committees.

Your Company has a designated e-mail ID, investorinfo@combatdrugs.in for the redressal of any Stakeholders' related grievances exclusively for the purpose of registering complaints by Members/ stakeholders. Your Company has also displayed the said email ID under the investors section at its website, and other relevant details prominently for creating investor/ stakeholder awareness. Your Company maintains a functional website containing necessary information about the Company, contact information of the designated officials of the Company and the contents of the said website are updated at any given point of time as per Clause 54 of the Listing Agreement, and as per the requirements of the Companies Act, 2013.

The Compliance Officer, monitors the share transfer process and reports to the Company's Board in each meeting and the said Officer also directly liaises with the authorities such as SEBI, Stock Exchanges, ROC etc., and investors with respect to implementation of various clauses, rules, regulations and other directives of such authorities and investor service & complaints related matter. Investors may address their Communications / Suggestions / Grievances to The Compliance Officer at 4th Floor, Plot No.94, Sagar Society, Road No.2, Banjara Hills, Hyderabad - 500034. TELANGANA. India. Or send a mail to investorinfo@combatdrugs.in / cs@combatdrugs.in

* Mr. Kumar Raghavan is the Compliance Officer of the Company.

3. GENERAL BODY MEETINGS :

Date, Time and Location of the last 3 Annual General Meetings are:

AGM	DATE	LOCATION	TIME
32nd	29.09.2018	1st Floor, Conference Hall, Goodlands Banquet, Opp. CCMB, Habsiguda X Roads, Hyderabad – 500 007	11:30 AM
31st	30.11.2017 Thursday	Plot No.112, Gayatri Nagar, Road No.14, Bouduppall, Hyderabad – 500039	3:00PM
30th	29.09.2016 Wednesday	Plot No.112, Gayatri Nagar, Road No.14, Bouduppall (V), R.R.District - 500039	11:00AM

Postal Ballot:

No Resolution was passed during the previous year, through Postal Ballot process.

Details of Non Compliance

(i) During the year 2018-19, no materially significant related party transactions have been entered into by the Company with the Promoters, Directors or Management or their relatives that may have a potential conflict with the interest of the Company. None of the Non-Executive Directors/ Independent Directors have any pecuniary material relationship or transactions with the Company for the year ended March 31, 2019, and have given undertakings to that effect.

(ii) Details of non-compliance by the Company, penalties, and strictures imposed on the Company by the Stock Exchange(s) or SEBI or any statutory authority, on any matter related to capital markets, during the last three years:

No penalty, or stricture was imposed by the Stock Exchanges or SEBI or any other authority, during the last 3 (three) years, since all applicable requirements were fully complied with.

(iii) Accounting treatment in preparation of Financial Statements:

The financial statements of the Company have been prepared and presented in accordance with the Indian Accounting Standards ("Ind AS") notified under the notified under Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment

Rules, 2016. For all periods upto and including the year ended 31 March, 2019, the company prepared its financial statements in accordance with accounting standards notified under Section 133 of the Companies Act 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014. The company has adopted all applicable standards and the adoption was carried out in accordance with Ind AS 101.

- (iv) Whistle Blower Policy: The Company has adopted a Whistle Blower Policy and has established the necessary mechanism in line with the requirements under the Companies Act, 2013 and Listing Agreement:
- For employees to report concerns about unethical behavior and to establish a mechanism to report to the management, concerns about unethical behavior, actual or suspected fraud or violation of the Integrity Policy; and
 - To ensure that adequate safeguards shall be provided to the whistle blowers against any victimization or vindictive practices like retaliation, threat or any adverse (direct or indirect) action on their employment. The Policy also ensures that strict confidentiality is maintained whilst dealing with concerns and also that no discrimination will be meted out to any person for a genuinely raised concern.
 - No personnel/ person has been denied access to the Audit Committee.
- (v) Your Company has laid down a Code of Conduct (“Code”) for all the Board Members and Senior Management Personnel of the Company. The Code is available on the website of the Company i.e., www.combatdrugs.in. All Directors and Personnel of the Company have affirmed compliance with the Company’s Code of Conduct for the financial year ended March 31, 2019. A declaration signed by the Chief Executive Officer (CEO)/ Managing Director to this effect is attached as Annexure A to the Corporate Governance Report in the Annual Report.
- (vi) The Company has disclosed and complied with all the mandatory requirements under SEBI (Listing Obligations and Disclosure Requirements). The details of these compliances have been given in the relevant sections of this report. Among the non-mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) the Company has complied with the following:
- Separate posts of Chairman and CEO - The Chairman and Managing Director/ CEO are two separate persons -The position of Chairman and CEO is bifurcated in the Company. The company will be appointing professional Managing Director and CEO shortly.
 - Your Company has comprehensive guidelines on prohibiting insider trading and the Company has adopted the code of internal procedures and conduct for listed companies notified by the SEBI

RECONCILIATION OF SHARE CAPITAL AUDIT

The 'Reconciliation of Share Capital Audit' was undertaken on a quarterly basis and the audit covers the reconciliation of the total admitted capital with NSDL and CDSL and the total issued and listed capital. The audit has also confirmed that the aggregate of the total issued/ paid-up-capital is in agreement with the total number of shares in physical form, shares allotted & advised for demat credit but pending execution and the total number of dematerialized shares held with NSDL and CDSL.

STATUTORY AND SECRETARIAL AUDITORS

The Auditors Report and Secretarial Auditor Report are given as Annexure which forms part of this report

Reporting of Frauds by auditors

During the year under review, the statutory auditors has not reported to the audit committee, under Section 143 (12) of the Companies Act, 2013, any instance of fraud committed against the Company by its officers or employees, the details of which would need to be mentioned in the Board's report.

Internal Audit & Controls

The Company has adequate Internal Financial Controls consistent with the nature of business and size of the operations, to effectively provide for safety of its assets, reliability of financial transactions with adequate checks and balances, adherence to applicable statutes, accounting policies, approval procedures and to ensure optimum use of available resources. These systems are reviewed and improved on a regular basis. It has a comprehensive budgetary control system to monitor revenue and expenditure against approved budget on an ongoing basis.

Vigil Mechanism:

In pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013, a Vigil Mechanism for Directors and employees to report genuine concerns has been established.

Risk Management Policy

The Risk Management Policy is in place in the Company which enables the Company to proactively take care of the internal and external risks of the Company and ensures smooth business operations.

The Company's risk management policy ensures that all its material risk exposures are properly covered, all compliance risks are covered and the Company's business growth and financial stability are assured. Board of

Directors decide the policies and ensure their implementation to ensure protection of Company from any type of risks.

CEO AND CFO'S CERTIFICATION

As required by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the CEO and CFO's Certification is provided as Annexure to the Corporate Governance Report in the Annual Report. As required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the CEO and CFO's / Managing Directors Certification of the Financial Statements, the Cash Flow Statement and the Internal Control Systems for financial reporting for the financial year ended March 31, 2019, was placed before the Board of Directors at all their meetings held.

MEANS OF COMMUNICATION

- Company has regularly furnished Financial Results by email and also by way of filing through the electronic filing within the time lines to the Bombay Stock Exchange.
- Quarterly and annual financial results are also published in English, and other regional (Telugu) newspapers.
- Website Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company's website www.combatdrugs.in contains all the information as may be required by the Shareholders including press releases, financial results, fact sheet reports, additional disclosures, earnings conference, shareholding pattern, Shareholders' reports, investor presentation, Annual Reports, etc., Quarterly results are put on the Company's web-site. The Company submitted a quarterly compliance report to the stock exchanges within 45 days from the close of quarter.

BSE Corporate Compliance & Listing Centre ('Listing Centre'):

BSE's Listing Centre is a web based application designed for Corporates. All periodical compliance filings like shareholding pattern, corporate governance report, media releases are electronically filed on the Listing Centre.

SEBI Complaints Redress System (SCORES):

Investor complaints are processed through a centralized web-based complaints redressal system. Centralised database of all complaints received, online upload of the Action Taken Reports (ATRs) by the Company, online viewing by investors of actions taken on the complaint and the current status are updated/resolved electronically in the SEBI SCORES system.

MARKET PRICE DATA

The closing market price of equity share on 31st March, 2019 (last trading day of the financial year) was Rs.26.20/- as compared to the price on 31st March 2018 of Rs. 20.20 on BSE. The current price (as on 30th October, 2019) is Rs. 19.00

The Thirty Third Annual General Meeting (AGM) of the Company for the financial year 2018-19 is scheduled on the 09th December, 2019 at 11.00 AM at 1st Floor, Conference Hall, Goodlands Banquet, opp. CCMB, Habsiguda X Roads, Hyderabad 500007, TELANGANA. India.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Mumbai Stock Exchange (BSE), the Company has also extended e-voting facility, for its Members to enable them to cast their votes electronically and also physically on the proposed resolutions in the Notice of the Thirty Third Annual AGM. Instructions for e-voting are listed under the segment "Notes" in the Notice to Thirty Third Annual AGM.

Those of the Shareholders/ Members, who cannot attend the AGM in person, can appoint a proxy to represent them in the AGM, for which the Shareholder/ Member needs to fill in a proxy form and send it to the Company, to its Registered Office address, on or before 10.30 AM on 01-12-2019.

11. GENERAL SHAREHOLDER INFORMATION:

Annual General Meeting	: 09th December, 2019 at 11:00A.M. at 1st Floor, Conference Hall, Goodlands Banquet, Opp. CCMB, Habsiguda X Roads, Hyderabad 500007, TELANGANA. India
Financial Year	: 1st April, 2018 to 31st March, 2019
Dates of Book Closure	: 30.11.2019 to 09.12.2019
Listing	: The Bombay Stock Exchange Ltd.
Stock Code	: 524752

Registrar & Transfer Agents : **Venture Capital & Corporate**
Investments Pvt Ltd, 12-10-167, Bharat
Nagar, Hyderabad - 500 018
Ph: +91-40+23818475 / 23818476
Fax:+91-40-23868024
E-mail:info@vccilindia.com
Contact: Mr. E.S.K.Prasad / P. Srinivas Reddy

Share Transfer System : The share transmission, sub-division, etc.
are affected within fifteen days from the date
of the lodgment.

Dematerialization of shares : The company was allotted ISIN
INE643N01012 by CDSL and NSDL and
trading is being done in Dematerialized form
in BSE.

Nomination Facility : Shareholders, holding shares in physical form
and desirous of making/ changing a
nomination in respect of their shareholding in
the Company as permitted the Companies
Act 2013 are requested to submit to the
Compliance Officer in the prescribed form
2B for this purpose, which can be furnished
by the Company on request.

Outstanding GDR's/ ADR's/
Warrant or any convertible
instruments, conversion date
and likely impact on equity. : Nil

Address for Correspondence : **Registered Office :**
Plot No. 94, 4th Floor, Road No. 2,
Sagar Society, Banjara Hills ,
Hyderabad -500034.Telangana, INDIA

Works:9-109/9, Plot No.112, Gayatri Nagar,
Road No.14, Boduppall, R.R.Dist - 500039.
TELANGANA. INDIA

1. DISTRIBUTION OF SHAREHOLDING :

Distribution Details Of Shares FOR THE PERIOD 31/3/2019

Shareholders holding nominal Value of	No. of Shareholders		Nominal Value of Shares Held and percentage of Equity	
	Number	% To Total	Value	% To Total
Upto - 5000	11532	98.2	2616900	3.27
5001 - 10000	84	0.72	671510	0.84
10001 - 20000	45	0.38	670660	0.84
20001 - 30000	14	0.12	350270	0.44
30001 - 40000	6	0.05	215340	0.27
40001 - 50000	9	0.08	417210	0.52
50001 - 100000	20	0.17	1407610	1.76
100001 and above	33	0.28	73650500	92.06
Total	11743	100	80000000	100

2. SHAREHOLDING PATTERN FOR THE QUARTER ENDED 31ST MARCH, 2019

S. No.	Category of shareholder	Nos. of share holders	No. of equity shares held	Shareholding as a % of total no. of shares
(A)	PROMOTER & PROMOTER GROUP			
	NRI Promoters: Individuals/			
	NRI / Individuals	1	4639927	58.00%
	Total Promoter Shareholding	1	4639927	58.00%
(B)	PUBLIC SHAREHOLDING			
1	Financial Institutions/Banks	2	1308	0.02%
2	Individual ShareHolders holding share capital upto 2Lakh	11671	715851	8.95%
3	Individual ShareHolders holding capital in excess of 2Lakh	20	2079950	26.00%
4	Bodies Corporate	36	558521	6.98%
5	Clearing Member	9	3218	0.04%
6	Non Resident Individuals	4	1225	0.02%
	TOTAL PUBLIC SHAREHOLDING	11742	3360073	42.00%
	GRAND TOTAL	11743	8000000	100%

For and on behalf of the Board
For COMBAT DRUGS LIMITED

Place: Hyderabad
 Date: 08.11.2019

Sd/-
 VASUDEV KOMMARAJU
 DIRECTOR

Sd/-
 SUSHANT MOHANLAL
 DIRECTOR

Annexure-A
TO CORPORATE GOVERNANCE

Declaration by the Director under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding compliance with Code of Conduct

In accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Stock Exchanges, I hereby confirm that, all Board Members and Senior Management Personnel of the Company have affirmed compliance with the Code of Conduct, as applicable to them, for the financial year ended March 31, 2019.

For and on behalf of the Board
For COMBAT DRUGS LIMITED

Place: Hyderabad
Date: 08.11.2019

Sd/-
VASUDEV KOMMARAJU
DIRECTOR

Sd/-
SUSHANT MOHANLAL
DIRECTOR

Annexure B to Corporate Governance
FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis

SL. No.	Particulars	Not At Arms Length	At Arms Length
1	Name (s) of the related party & nature of relationship	NIL	--
2	Nature of contracts / arrangements / transaction.	NIL	--
3	Duration of the contracts / arrangements / transaction	NIL	--
4	Salient terms of the contracts or arrangements or transaction including the value, if any	NIL	--
5	Justification for entering into such contracts or arrangements or transactions'	NIL	N/A
6	Date of approval by the Board	NIL	29-09-2018
7	Amount paid as advances, if any	NIL	NIL
8	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	NIL	29-09-2018

NOTE: The details of names, nature of relationship; nature of such contracts / arrangements / transactions are disclosed in Note No.20(iv) of the Financial Statements

For **COMBAT DRUGS LIMITED**

Place: Hyderabad
Date: 09.11.2019

Sd/-
VASUDEV KOMARAJU
DIRECTOR

Annexure-C to Corporate Governance

CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION

I, Mr. Vasudev Kommaraju, CEO & Director and Sonam Jalan, CFO of Combat Drugs Limited to the best of my knowledge, information and belief, certify that:

- 1) We have reviewed financial statements and the cash flow statement for the year ended March 31, 2019:
 - a) These statements do not contain any materially untrue statement or omit any Material fact or contain statements that might be misleading;
 - b) These statements together present, in all material respects, a true and fair view of the Company's affairs, the financial condition and results of operations and are in compliance with applicable accounting standards, laws and regulations.
- 2) There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or which violate the Company's code of conduct.
- 3) We are responsible for establishing and maintaining internal controls over financial reporting by the Company and we have:
 - a) Designed such controls to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others;
 - b) Designed or caused to be designed, such internal control systems over financial reporting, so as to provide reasonable assurance regarding the preparation of financial statements in accordance with Indian accounting standards (INDS AS) notified under the companies (Indian accounting standards) Rules; and
 - c) Evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting.
- 4) During the year, we have disclosed to the Company's Auditors and the Audit Committee of the Board of Directors:
 - a) Any change, that has materially affected or is reasonably likely to materially affect, the Company's internal control over financial reporting;
 - b) Any significant changes in accounting policies during the year, and that the same have been disclosed appropriately in the notes to the financial statements;

- c) Instances of significant fraud, if any, that we are aware especially, if any,
Member of management or employee involved in financial reporting related process. No such instances were noticed during the year 2018-19;
- d) All significant changes and deficiencies, if any, in the design or operation of internal controls, which could adversely affect the Company's ability to record, process, summarize and report financial data; and
- e) Any material weaknesses in internal controls over financial reporting including any corrective actions with regard to deficiencies.
- 5) In the event of any materially significant misstatements or omissions, we will return to the Company that part of any bonus or incentive which was inflated on account of such mistakes or omissions.
- 6) We affirm that we have not denied any employee, access to the Audit Committee of the Company (in respect of matters involving alleged misconduct) and we have provided protection to whistleblowers from unfair termination and other unfair or prejudicial employment practices.
- 7) We further declare that, all Board Members and Senior Managerial personnel have affirmed compliance with the code of conduct for the current year.

For COMBAT DRUGS LIMITED

Sd/-
VASUDEV KOMARAJU
DIRECTOR

Sd/-
SONAM JALAN
CHIEF FINANCIAL OFFICER

Place: Hyderabad
Date: 08.11.2019

**FORM MR-3
SECRETARIAL AUDIT REPORT**

**[Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and
Remuneration Personnel) Rules, 2014]**

FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2019

To
The Members of
M/s. Combat Drugs Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Combat Drugs Limited (hereinafter called "the Company").

Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon. Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2018 and ended 31st March, 2019, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter :

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s. Combat Drugs Limited ("The Company") for the financial year ended on 31st March, 2019, according to the provisions of:
 - iii. The Companies Act, 2013 (the Act) and the rules made thereunder for specified sections notified and came into effect from 12th September, 2013 and sections and Rules notified and came into effect from 1st April, 2014 ;
 - iv. The Securities Contracts (Regulation) Act, 1956 ("SCRA") and the Rules made thereunder;
 - v. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
 - vi. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment (FDI), Overseas Direct Investment, and External Commercial Borrowings (not applicable during the audit period);

- vii. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - i. The Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015;
 - ii. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - iii. The Securities and Exchange Board of India (SEBI) (Prohibition of Insider Trading) Regulations, 1992;
 - iv. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client;
 - vi. Other applicable laws, including the following:
 - (a) Employees State Insurance Act 1948
 - (b) Income-tax Act 1961
 - (c) Drugs and Cosmetics Act, 1940
2. Provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act) were not applicable to the Company during the audit period:
 - i. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
 - ii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009;
 - iii. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998;
 - iv. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008
 - v. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
3. We have also examined compliance with the applicable clauses of the following:
 - i. Secretarial Standards issued by The Institute of Company Secretaries of India to the extent applicable under the provisions of Companies Act, 2013 and
 - ii. The Listing Agreements entered into by the Company with the Bombay Stock Exchange Limited;

4. We further report that:

- (a) The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the year under review were carried out in compliance with the provisions of the Companies Act, 2013.
- (b) Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation of the meeting.
- (c) Majority decision is carried through while the dissenting members' views, if any, are captured and recorded as part of the minutes.

5. We further report that there are adequate systems and processes in the Company with the size and operation of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

Place: Hyderabad,
Date: 30th July, 2019

For MARTHI & CO,
Company Secretaries
Sd/-
S S MARTHI
PROPRIETOR
FCS 1989, CP 1937

ANNEXURE - E

Form No. MGT-9

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON 31ST MARCH 2019

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

- i. CIN : CL23230TG1986PLC006781
ii. Registration Date : 17-09-1986
iii. Name of the Company : COMBAT DRUGS LIMITED
iv. Category / Sub-Category : Company Limited by shares and of the Company Indian Non-Government Company
v. Address of the Registered office and contact details As per Last Year annual Return : 4th Floor, Plot No.94, Sagar Society, Road No.2, Banjara Hills, Hyd- 39. TELANGANA. India.
vi. Whether listed company : Yes
vii. Name, Address and Contact details of Registrar and Transfer Agent, if any : M/s Venture Capital & Corporate Services Pvt Ltd 12-10-167, Bharat Nagar, Hyderabad-500 018, Telangana.
Phone: (+91)-4023818475/476
Fax: +91 40 23868024
Email Id: Info@Vccipl.Com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

S No.	Name and Description of main products / services	NIC Code of the Product/ service	% of Total Turnover of the Company
1	Pharmaceutical Products	2100	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S No.	Name and Description of main products / services	CIN/GLN	Holding/ Subsidiary / Associate	% of Shares Held	Applicable Section
1	Pharmaceuticals		Subsidiary	100%	
2	Information Technology		Subsidiary	100%	

I. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Share Holding

S.No	Category of shareholder	AT THE BEGINNING OF THE YEAR			As a % of Total Shares	AT THE END OF THE YEAR			As a % of Total Shares	DIFFERENCE IN SHAREHOLDING
		DEMAT	PHYSICAL	TOTAL		DEMAT	PHYSICAL	TOTAL		
(A) Promoter & Promoter Group										
	NRI / Individual	46,39,927	0	46,39,927	58.00%	46,39,927	0	46,39,927	58.00%	0.00%
	TOTAL PROMOTER SHAREHOLDING	46,39,927	0	46,39,927	58.00%					
(B) PUBLIC SHAREHOLDING										
1	Financial Institutions/Banks	1,008	300	1,308	0.02%	1,008	300	1,308	0.02%	0.00%
2	Individual ShareHolders holding share capital upto 2Lakh	4,67,317	2,71,051	7,38,368	9.23%	4,71,386	2,44,465	7,15,851	8.95%	-0.28%
3	Individual ShareHolders holding capital in excess of 2Lakh	12,84,954	5,81,718	18,66,672	23.33%	15,53,232	5,26,718	20,79,950	26.00%	2.67%
4	Bodies Corporate	3,22,138	3,89,326	7,11,464	8.89%	5,40,281	18,240	5,58,521	6.98%	-1.91%
5	Clearing Member	41,161	0	41,161	0.51%	3,218	0	3,218	0.04%	-0.47%
6	Non Resident Individuals	1,100	0	1,100	0.01%	1,225	0	1,225	0.02%	0.00%
	TOTAL PUBLIC SHAREHOLDING	21,17,678	12,42,395	33,60,073	42.00%	25,70,350	7,89,723	33,60,073	42.00%	0.00%
	GRAND TOTAL	67,57,605	12,42,395	80,00,000	100.00%	72,10,277	7,89,723	80,00,000	100.00%	

ii. Shareholding of Promoters

S.No	Shareholder Name	Holding at beginning of the Year			Holding at End of the Year			% change during the year
		No. of Shares	% of Equity	% pledged	No. of Shares	% of Equity	% pledged	
1	Janakiram Ajjrapu	4639927	58.00%	0	4639927	58.00%	0	-
	Total	4639927	58.00%	0	4639927	58.00%	0	

iii. Change in Promoters' Shareholding (please specify, if there is no change)
Nil

**iv) Shareholding Pattern of top ten Shareholders:
(Other than Directors, Promoters and Holders of GDRs and ADRs):**

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
1	SUSHANT MOHAN LAL				
	At the beginning of the year	6,55,200	8.19	6,55,200	8.19
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	No Change			
	At the end of the year (or on the date of separation, if separated during the year)	6,55,200	8.19	6,55,200	8.19

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
2	SESHU SRINIVAS AKULA				
	At the beginning of the year	384273	4.80	384273	4.80
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	No Change			
	At the end of the year (or on the date of separation, if separated during the year)	384273	4.80	384273	4.80

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
3	Goldsmith Landmarks Pvt Ltd				
	At the beginning of the year	-	-	-	-
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	Change is due to Acquisition of Shares			
	At the end of the year (or on the date of separation, if separated during the year)	370896	4.84	370896	4.84

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
4	Gudipudi Venkateshwar Rao				
	At the beginning of the year	200000	2.50	200000	2.50
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	No Change			
	At the end of the year (or on the date of separation, if separated during the year)	200000	2.50	200000	2.50

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
5	Accura Projects & Infrastructures (India) Pvt Ltd	No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
	At the beginning of the year	150294	1.88	150294	1.88
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	No Change			
	At the end of the year (or on the date of separation, if separated during the year)	150294	1.88	150294	1.88

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
6	Umesh Narayan	No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
	At the beginning of the year	50537	0.63	50537	0.63
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	Acquired during the year			
	At the end of the year (or on the date of separation, if separated during the year)	180537	2.26	180537	2.26

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
7	HSE Securities Limited				
	At the beginning of the year	130000	1.63	130000	1.63
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	Sale during the year			
	At the end of the year (or on the date of separation, if separated during the year)	0	0	0	0

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
8	Suresh Gadaley				
	At the beginning of the year	25	0.00	25	0.00
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	Acquired during the year			
	At the end of the year (or on the date of separation, if separated during the year)	100083	1.25	100083	1.25

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
9	Ram Kumar Sarma V				
	At the beginning of the year	77445	0.97	77445	0.97
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	No Change			
	At the end of the year (or on the date of separation, if separated during the year)	77445	0.97	77445	0.97

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
10	Sree Ram Ratan Volety				
	At the beginning of the year	65000	0.81	65000	0.81
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	No Change			
	At the end of the year (or on the date of separation, if separated during the year)	65000	0.81	65000	0.81

v). Shareholding of Directors and Key Managerial Personnel:

S. No	Particulars	Shareholding at the beginning of the year		Cumulative Share holding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
1	SUSHANT MOHAN LAL				
	At the beginning of the year	6,55,200	8.19	6,55,200	8.19
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/bonus/ sweat equity etc.):	No Change			
	At the end of the year (or on the date of separation, if separated during the year)	6,55,200	8.19	6,55,200	8.19

No other Director Holds any Equity Shares in the company

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment.

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total
Indebtedness at the beginning of the financial year				
i) Principal Amount				
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not	-	-	-	-
Total (i+ii+iii)	Nil	Nil	Nil	Nil
Change in Indebtedness during the financial year				
- Addition	-	-	-	-
- Reduction	-	-	-	-
Net Change	-	-	-	-
Indebtedness at the end of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	-	-	-	-
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

Sl. No	Particulars of Remuneration	Name of MD/WTD/ Manager			Total Amount
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	WTD Sushant Mohan Lal	MAN		9,00,000
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961				
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961				
2.	Stock Option	--	NIL	--	NIL
3.	Sweat Equity		NIL		NIL
4.	Commission - as % of profit - others, specify...		NIL		NIL
5.	Others, please specify		NIL		NIL
6.	Total (A)		NIL		9,00,000
	Ceiling as per the Act				

B. Remuneration to other directors:

Independent Directors • Fee for attending board committee meetings Nil

Sl. No	Particulars of Remuneration	Name of MD/WTD/ Manager			Total Amount
	Independent Directors • Fee for attending board committee meetings • Commission • Others, please specify	Nil			Nil
	Total (1) Other Non-Executive Directors • Fee for attending board committee meetings • Commission • Others, please specify	Nil			Nil
	Total (2)	Nil			Nil
	Total (B)=(1+2)	Nil			Nil
	Total Managerial Remuneration	Nil	Nil	Nil	Nil
	Overall Ceiling as per the Act				

C. Remuneration to Key Managerial Personnel Other Than MD /Manager / WTD

Sl. No.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	NIL	1,00,000	NIL	1,00,000
2.	Stock Option				
3.	Sweat Equity				
4.	Commission - as % of profit - others, specify...				
5.	Others, please specify				
6.	Total	NIL	1,00,000	NIL	1,00,000

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the companies Act	Brief description	Details of Penalty/ Punishment/ Compounding fees imposed	Authority [RD/ /NCLT/ Court]	Appeal made. If any (give details)
A. Company					
Penalty					
Punishment					
Compounding		NIL	NIL	NIL	
B. Directors					
Penalty		NIL	NIL	NIL	
Punishment					
Compounding					
C. Other Officers In Default					
Penalty		NIL	NIL	NIL	
Punishment					
Compounding					

INDEPENDENT AUDITORS' REPORT

To
The Members of Combat Drugs Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Combat Drugs Limited ("the Company"), which comprise the Balance Sheet as at 31st March 2019, and the Statement of Profit and Loss (including Other Comprehensive Income), and the Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2019, and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone

financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to communicate in our report.

Information Other than the Standalone financial statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the standalone financial statements, consolidated financial statements and our auditor's report thereon. The other information is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the other information, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Management's Responsibility for the Standalone financial statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the IND AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing,

as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone financial statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required

to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act based on our audit, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act read with Rule 7 of Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”.
- (g) With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

- (h) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its standalone financial position;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;

- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
2. As required by the Companies (Auditor's Report) Order, 2016, ("the Order") issued by the Central Government of India in terms of Section 143 (11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Sd/-

A.V.Sadasiva
Partner - M.No.018404

Place: Hyderabad.
Date: 29th May, 2019

Annexure - A to the Independent Auditors' Report

(Referred to in paragraph 1(f) under 'Report on Other Legal Regulatory Requirements' section of our report to the Members of the Company of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Combat Drugs Limited ("the Company") as of 31 March 2019 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls: The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility: Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone

financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting: A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting: Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion: In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Sd/-

A.V.Sadasiva
Partner - M.No.018404

Place: Hyderabad.
Date: 29th May, 2019

Annexure - B to the Independent Auditors' Report

With reference to Paragraph 2 under 'Report on Other Legal Regulatory Requirements' section of our report to the Members of the Company, we report that

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) As explained to us, the fixed assets have been physically verified by the management in a periodical manner, which in our opinion is reasonable, having regard to the size of the company and the nature of its business. No material discrepancies were noticed on such physical verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no immovable properties were held by the Company.
- (ii) The inventories have been physically verified during the year by the management. The discrepancies noticed on verification between the physical stocks and book records were not material.
- (iii) The Company has granted unsecured loan to two wholly owned subsidiaries covered in the register maintained under section 189 of the Act.
In our opinion and according to the information given to us, the term and conditions of the loan given by the Company are prima facie, not prejudicial interest of the Company
The schedule of repayment of principal and payment of interest has been stipulated and repayments of principal and receipt of interest are not due as on balance sheet date.
There are no overdue amounts as at the year-end in respect of both principal and interest.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Section 185 and 186 of the Act in respect of grant of loans and making investments as applicable.
- (v) The Company has not accepted deposits within the meaning of the provisions of sections 73 to 76 or any other relevant provisions of the Act and the rules framed there under.
- (vi) Maintenance of cost records by the company has not been prescribed by Central Government of India under sub-section (1) of section 148 of the Companies Act, 2013. Accordingly, paragraph 3 (vi) of the Order is not applicable.
- (vii) (a) According to the information and explanations given to us and the records of the Company examined by us, the Company is regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, customs duty, goods and service tax, cess and any other statutory dues as applicable with the appropriate authorities and there were no arrears of outstanding statutory dues as at the last day of the financial year concerned for a

period of more than six months from the date they became payable except an amount of Rs. 0.21 lakhs due with respect to professional tax for more than six months.

- (b) According to the information and explanations given to us and records of the Company examined by us, there are no disputes pending against the company as at 31st March, 2019.
- (viii) The Company has not taken any loans or borrowing from a financial institution, banks and Governments during the financial year. Accordingly, paragraph 3 (viii) of the Order is not applicable.
- (ix) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments). The company is not having any term loans, hence the paragraph 3(ix) of the order is not applicable.
- (x) To the best of our knowledge and belief and according to the information and explanations given to us, no fraud on or by the Company was noticed or reported during the year.
- (xi) According to the information and explanations give to us and based on our examination of the records of the Company, the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- (xii) In our opinion and according to the information and explanations given to us, the Company is not a Nidhi company. Accordingly, paragraph 3 (xii) of the Order is not applicable.
- (xiii) According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with section 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3 (xv) of the Order is not applicable.
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Sd/-

A.V.Sadasiva
Partner - M.No.018404

Place: Hyderabad.
Date: 29th May, 2019

COMBAT DRUGS LIMITED
STANDALONE BALANCE SHEET AS AT 31 March 2019
All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Note	31 March 2019	31 March 2018
I. ASSETS			
Non-current Assets			
(a) Property, Plant and Equipment	3	0.70	-
(b) Financial assets			
(i) Investments	4	4.56	0.05
(c) Other non-current assets	5	0.30	0.30
Current Assets			
(a) Inventories	6	32.15	9.73
(b) Financial assets			
(i) Trade receivables	7.1	303.69	58.78
(ii) Cash and cash equivalents	7.2	1.76	2.29
(iii) Other financial assets	7.3	19.22	3.51
(c) Current tax assets	8	0.06	-
(d) Other current assets	9	221.39	221.54
TOTAL ASSETS		583.83	296.20
II. EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	10	800.00	800.00
(b) Other equity	11	(550.29)	(587.98)
Liabilities			
Non-Current Liabilities			
(a) Deferred tax liabilities	12	0.01	-
Current Liabilities			
(a) Financial liabilities			
(i) Borrowings	13.1	13.87	13.30
(ii) Trade payables	13.2		
a) Total outstanding dues of Micro enterprises and small enterprises		-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises		313.40	55.89
(iii) Other Financial liabilities	13.3	6.04	14.42
(b) Other current liabilities	14	0.80	0.57
TOTAL EQUITY AND LIABILITIES		583.83	296.20

Summary of significant accounting policies

2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For M. Anandam & Co

For and on behalf of the Board

Chartered Accountants

Firm Registration Number: 0001255

Sd/-

Sd/-

Sd/-

A V Sadasiva

Vasudev Kommaraju Sushant Mohan Lal

Partner

Wholetime Director

Director

M.No. 018404

DIN: 07233691

DIN: 01227151

Place: Hyderabad

Date: 29.05.2019

COMBAT DRUGS LIMITED
STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 March 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Note	31 March 2019	31 March 2018
I. Revenue from operations	15	678.11	101.63
II. Other income	16	0.88	11.37
III. Total revenue (I + II)		678.99	113.00
IV. Expenses			
Cost of materials consumed	17	614.72	43.42
Changes in inventories of finished goods and stock in trade	18	(22.42)	(2.70)
Employee benefits expense	19	16.68	24.94
Depreciation expenses	3	0.06	-
Other expenses	20	32.25	29.10
Total expenses		641.29	94.76
V. Profit/(Loss) before tax (III - IV)		37.70	18.24
VI. Tax expense:			
(1) Current tax		-	-
(2) Deferred tax	12	0.01	-
VII. Profit/(Loss) for the period (V-VI)		37.69	18.24
VIII. Other comprehensive income		-	-
IX. Total comprehensive income for the year		37.69	18.24
X. Earning per equity share (Face Value of Rs. 10/- each)			
(1) Basic		0.47	0.23
(2) Diluted		0.47	0.23

Summary of significant accounting policies

2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For M. Anandam & Co

Chartered Accountants

Firm Registration Number: 0001255

For and on behalf of the Board

Sd/-

A V Sadasiva

Partner

M.No. 018404

Place: Hyderabad

Date: 29.05.2019

Sd/-

Vasudev Kommaraju

Director

DIN: 07233691

Sd/-

Sushant Mohan Lal

Director

DIN: 01227151

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

1. Background

Combat Drugs Limited was incorporated in 1989 having its registered office in Hyderabad. The Company deals in trading and manufacturing of Pharmaceutical drugs.

These Financial Statements of the Company as at and for the year ended 31st March, 2019 (including comparatives) were approved and authorised for issue by the Board of Directors of the Company on 29th May, 2019.

2. Significant Accounting Policies

This note provides a list of the significant accounting policies adopted in the preparation of the financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

a) Statement of Compliance

The financial statements are prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Amendment Rules, 2016 and Companies (Indian Accounting Standards) Amendment Rules, 2017, the relevant provisions of the Companies Act, 2013 ('the Act') and guidelines issued by the Securities and Exchange Board of India (SEBI), as applicable.

b) Basis of preparation

The financial statements have been prepared under the historical cost convention with the exception of certain assets and liabilities that are required to be carried at fair values by Ind AS. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

c) Use of estimates and critical accounting judgements

In preparation of the financial statements, the Company makes judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and the associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and the underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and future periods affected.

Significant judgements and estimates relating to the carrying values of assets and liabilities include useful lives of property, plant and equipment and intangible assets, impairment of property, plant and equipment, intangible assets and investments, provision for employee benefits and other provisions, recoverability of deferred tax assets, commitments and contingencies.

d) Revenue Recognition

i) Sale of products

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the amount can be reliably measured. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, usually on delivery / dispatch of the goods. Revenue from the sale of goods is measured at the value of the consideration received or receivable, net of returns, discounts, volume rebates.

ii) Other income

Dividend income is recognised when the shareholder's right to receive the income is established.

Interest income is recognized on time proportion basis taking into account the amount outstanding and the rate applicable.

e) Income tax

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in the countries where the Company operates and generates taxable income.

Current income tax relating to items recognised outside profit or loss is recognised in outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date. Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

f) Impairment of assets

Property, plant and equipment and intangible assets are tested for impairment annually whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

g) Cash and cash equivalents

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

h) Trade receivables

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using effective interest method, less provision for impairment.

i) Inventories

Raw Materials, Fuel, Stores & Spares and Packing Materials

Valued at lower of cost and net realizable value (NRV). However, these items are considered to be realizable at cost, if the finished products, in which they will be used, are expected to be sold at or above cost, Cost is determined on weighted Average basis.

Work-in-Progress (WIP) and Finished Goods

Valued at lower of cost and NRV. Cost of Finished Goods and WIP includes cost of raw materials, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Cost of inventories is computed on weighted average basis

j) other financial assets

i) Classification

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through profit or loss), and
- those measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in Statement of profit or loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Company has made an irrevocable election at the time of initial recognition to account for equity investment at fair value through other comprehensive income.

The Company reclassifies debt investments when and only when its business model for managing those assets changes.

ii) Measurement

At initial recognition, the company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the

financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in profit or loss.

Amortised cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost.

Fair value through other comprehensive income (FVOCI): Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognised in profit and loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss and recognised in other gains/(losses). Interest income from these financial assets is included in other income using the effective interest rate method.

Fair value through profit or loss: Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the statement of profit and loss in the period in which it arises. Interest income from these financial assets is included in other income.

Equity instruments:

The Company subsequently measures all equity investments at fair value. Where the company's management has elected to present fair value gains and losses on equity investments in other comprehensive income, there is no subsequent reclassification of fair value gains and losses to profit or loss. Dividends from such investments are recognised in profit or loss as other income when the Company's right to receive payments is established.

Changes in the fair value of financial assets at fair value through profit or loss are recognised in the other income. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

iii) Impairment of financial assets

The Company assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost and FVOCI debt instruments. The impairment methodology applied depends on whether there has been a significant increase in credit risk. Note 20 details how the Company determines whether there has been a significant increase in credit risk.

For trade receivables only, the Company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

iv) Derecognition of financial assets

A financial asset is derecognized only when

- The Company has transferred the rights to receive cash flow from the financial asset or
- retains the contractual rights to receive the cash flows of the financial assets, but assumes a contractual obligation to pay cash flows to one or more recipients.

Where the entity has transferred an asset, the Company evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is derecognized. Where the entity has not transferred substantially all risks and rewards of ownership of the financial asset is not derecognized.

Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is derecognised if the Company has not retained control of the financial asset. Where the Company retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

k) Offsetting financial instruments

Financial assets and liabilities are offset and the net amount is reported in the balance sheet where there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

l) Property, plant and equipment

Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Depreciation/Amortisation methods, estimated useful lives and residual value

Depreciation is calculated using the straight-line basis at the rates arrived at based on the useful lives prescribed in Schedule II of the Companies Act, 2013. The company follows the policy of charging depreciation on pro-rata basis on the assets acquired or disposed off during the year. Leasehold assets are amortised over the period of lease.

The residual values are not more than 5% of the original cost of the asset. The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains or losses on disposal are determined by comparing proceeds with carrying amount.

m) Trade and other payables

These amounts represent liabilities for goods and services provided to the company prior to the end of financial year which are unpaid. The amounts are unsecured and are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.

n) Borrowings

Borrowings are initially recognized at fair value, net of transaction cost incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognized as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent there is no evidence that it is probable that some or all the facility will be drawn down, the fee is capitalized as a prepayment for liquidity services and amortized over the period of the facility to which it relates.

Borrowings are removed from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

Where the terms of a financial liability are renegotiated and the entity issues equity instruments to a creditor to extinguish all or part of the liability (debt

for equity swap), a gain or loss is recognized in profit or loss, which is measured as the difference between the carrying amount of the financial liability and the fair value of the equity instrument issued.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period. Where there is a breach of a material provision of a long-term loan arrangement on or before the end of the reporting period with the effect that the liability becomes payable on demand on the reporting date, the entity does not classify the liability as current, if the lender agreed, after the reporting period and before the approval of financial statements for issue, not to demand payment as consequence of the breach.

o) Borrowing costs

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing cost eligible for capitalization.

Other borrowings costs are expensed in the period in which they are incurred.

p) Provisions

Provisions for legal claims and returns are recognised when the company has a present legal or constructive obligation as a result of past event, it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are not recognised for future operating losses.

Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provisions due to the passage of time is recognized as interest expense.

q) Employee benefits

Short-term obligations

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees' services up to the end of the reporting period and are

measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

r) Contributed equity

Equity shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

s) Dividends

Provision is made for the amount of any dividend declared, being appropriately authorized and no longer at the discretion of the entity, on or before the end of the reporting period but not distributed at the end of the reporting period.

t) Earning per share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- The profit attributable to owners of the company
- By the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares.

(ii) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- The after income tax effect of interest and other financing costs associated with dilutive potential equity shares, and
- The weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

u) Segment Reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker.

v) Rounding of amounts

All amounts disclosed in the financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Schedule III, unless otherwise stated.

w) Recent accounting pronouncements

- a) Ind AS 116 Leases: On March 30, 2019, Ministry of Corporate Affairs has notified Ind AS 116, Leases. Ind AS 116 will replace the existing leases Standard, Ind AS 17 Leases, and related Interpretations. The Standard sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract i.e., the lessee and the lessor. Ind AS 116 introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for all leases with a term of more than twelve months, unless the underlying asset is of low value. Currently, operating lease expenses are charged to the statement of Profit and Loss. The Standard also contains enhanced disclosure requirements for lessees. Ind AS 116 substantially carries forward the lessor accounting requirements in Ind AS 17.

The effective date for adoption of Ind AS 116 is annual periods beginning on or after April 1, 2019. The standard permits two possible methods of transition:

- Full retrospective – Retrospectively to each prior period presented applying Ind AS 8 Accounting Policies, Changes in Accounting Estimates and Errors
- Modified retrospective – Retrospectively, with the cumulative effect of initially applying the Standard recognized at the date of initial application.

Under modified retrospective approach, the lessee records the lease liability as the present value of the remaining lease payments, discounted at the incremental borrowing rate and the right of use asset either as:

- Its carrying amount as if the standard had been applied since the commencement date, but discounted at lessee's incremental borrowing rate at the date of initial application or
- An amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments related to that lease recognized under Ind AS 17 immediately before the date of initial application.

Certain practical expedients are available under both the methods. There is no impact on the financial statements on account of this amendment as Company does not have any lease transaction.

b) Ind AS 12 Appendix C, Uncertainty over Income Tax Treatments:

On March 30, 2019, Ministry of Corporate Affairs has notified Ind AS 12 Appendix C, Uncertainty over Income Tax Treatments which is to be applied while performing the determination of taxable profit (or loss), tax bases, unused tax losses, unused tax credits and tax rates, when there is uncertainty over income tax treatments under Ind AS 12. According to the appendix, companies need to determine the probability of the relevant tax authority accepting each tax treatment, or group of tax treatments, that the companies have used or plan to use in their income tax filing which has to

be considered to compute the most likely amount or the expected value of the tax treatment when determining taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates. The standard permits two possible methods of transition - i) Full retrospective approach – Under this approach, Appendix C will be applied retrospectively to each prior reporting period presented in accordance with Ind AS 8 – Accounting Policies, Changes in Accounting Estimates and Errors, without using hindsight and ii) Retrospectively with cumulative effect of initially applying Appendix C recognized by adjusting equity on initial application, without adjusting comparatives.

The effective date for adoption of Ind AS 12 Appendix C is annual periods beginning on or after April 1, 2019. The Company will adopt the standard on April 1, 2019 and has decided to adjust the cumulative effect in equity on the date of initial application i.e. April 1, 2019 without adjusting comparatives.

The effect on adoption of Ind AS 12 Appendix C would be insignificant in the standalone financial statements.

c) Amendment to Ind AS 12 – Income taxes :

On March 30, 2019, Ministry of Corporate Affairs issued amendments to the guidance in Ind AS 12, 'Income Taxes', in connection with accounting for dividend distribution taxes.

The amendment clarifies that an entity shall recognise the income tax consequences of dividends in profit or loss, other comprehensive income or equity according to where the entity originally recognised those past transactions or events.

Effective date for application of this amendment is annual period beginning on or after April 1, 2019. The Company is currently evaluating the effect of this amendment on the financial statements.

d) Amendment to Ind AS 19 –

Plan amendment, curtailment or settlement- On March 30, 2019, Ministry of Corporate Affairs issued amendments to Ind AS 19, 'Employee Benefits', in connection with accounting for plan amendments, curtailments and settlements.

The amendments require an entity:

- to use updated assumptions to determine current service cost and net interest for the remainder of the period after a plan amendment, curtailment or settlement; and
- to recognise in profit or loss as part of past service cost, or a gain or loss on settlement, any reduction in a surplus, even if that surplus was not previously recognised because of the impact of the asset ceiling.

Effective date for application of this amendment is annual period beginning on or after April 1, 2019. There is no impact on the financial statements on account of this amendment.

Notes to the financial statements for the year ended 31st March, 2019

3 Property, Plant and Equipment

Changes in the carrying value property, plant and equipment for the year ended 31st March, 2019

All amounts in ₹ Lakhs, unless otherwise stated

Sr. No	Particulars	Plant and Equipment	Computers	Total
1	Gross Carrying Amount			
	As at 1st April, 2018	-	-	-
	Additions	0.41	0.18	0.59
	Disposal / Adjustments	-	-	-
	As at 31st March, 2019	0.41	0.18	0.59
2	Depreciation			
	As at 1st April, 2018	-	-	-
	Charge for the year	0.06	-	0.06
	Disposal / Adjustments	-	-	-
	As at 31st March, 2019	0.06	-	0.06
3	Net Block			
	As at 31st March, 2019	0.35	0.18	0.53

3.1 Other Intangible Assets - Computer Software

Changes in the carrying value other intangible assets for the year ended 31st March, 2019

Sr. No	Particulars	Rs. In Lakh
1	Gross Carrying Amount	
	As at 1st April, 2018	-
	Additions	0.17
	As at 31st March, 2019	0.17
2	Amortisation	
	As at 1st April, 2018	-
	Charge for the year	-
	As at 31st March, 2019	-
3	Net Block	
	As at 31st March, 2019	0.17

COMBAT DRUGS LIMITED

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

4. Investments

Particulars	31 March 2019	31 March 2018
Investments in Equity Instruments (Unquoted - at cost)		
Wholly owned subsidiaries		
RA LABS Pte Ltd, Singapore (7,122(P.Y 100) Equity Shares of SGD 1/- each)	3.56	0.05
ICP Solutions Private Limited (10,000(P.Y Nil) Equity Shares of Rs. 10/- each)	1.00	-
TOTAL	4.56	0.05
Total amount of Aggregate value of unquoted investments	4.56	0.05

5. Other Non-Current assets

Particulars	31 March 2019	31 March 2018
Deposit - Rent	0.30	0.30
TOTAL	0.30	0.30

6. Inventories (Valued at Lower of Cost and NRV, Unless otherwise stated)

Particulars	31 March 2019	31 March 2018
a) Packing Materials	4.78	4.92
b) Finished goods	27.37	4.81
TOTAL	32.15	9.73

7.1 . Trade receivables

Particulars	31 March 2019	31 March 2018
a) Trade Receivables considered good - Unsecured	303.69	58.78
TOTAL	303.69	58.78

7.2. Cash and cash equivalents

Particulars	31 March 2019	31 March 2018
a) Balances with banks in current accounts	1.21	2.28
b) Cash on hand	0.55	0.01
TOTAL	1.76	2.29

7.3. Other financial assets (current)

Particulars	31 March 2019	31 March 2018
Advance given to Subsidiary Companies	18.68	3.51
Interest Receivable - Loans to Subsidiaries	0.54	-
TOTAL	19.22	3.51

8. Current tax asset

Particulars	31 March 2019	31 March 2018
TDS Receivable	0.06	-
TOTAL	0.06	-

9. Other current assets

Particulars	31 March 2019	31 March 2018
Advances to Suppliers	-	0.11
Others	-	0.04
Deposit with others	221.39	221.39
TOTAL	221.39	221.54

COMBAT DRUGS LIMITED
 NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

10. Equity share capital

Particulars	31 March 2019	31 March 2018
AUTHORIZED:		
80,00,000 Equity Shares of ₹10/- each (P Y 80,00,000 Equity Shares of ₹10/- each)	800.00	800.00
TOTAL	800.00	800.00
ISSUED, SUBSCRIBED & PAID-UP CAPITAL		
80,00,000 Equity Shares of ₹10/- each (P Y 80,00,000 Equity Shares of ₹10/- each)	800.00	800.00
TOTAL	800.00	800.00

(A) Movement in equity share capital:

Particulars	Number of shares	Amount
Balance at April 01, 2018	80.00	800.00
Movement during the year	-	-
Balance at March 31, 2019	80.00	800.00

(B) Details of shareholders holding more than 5% shares in the Company

Name of the shareholder	31 March 2019		31 March 2018	
	No. of Shares	% holding	No. of Shares	% holding
Janakiram Ajjarapu	46,39,927	58.00	46,39,927	58.00
Sushant Mohan Lal	6,55,200	8.19	6,55,200	8.19

(C) Terms/Rights attached to equity shares

The Company has only one class of equity shares having a face value of ₹ 10 /- each. Each holder of equity share is entitled to one vote per share. The Company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation of the company, the equity shareholders will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(D) The Company has not issued any share as fully paid up without payment being received in cash or as bonus shares nor any share has been bought back by the Company since its incorporation.

11. Other equity

Particulars	31 March 2019	31 March 2018
Reserves and surplus		
Retained Earnings	(550.29)	(587.98)
TOTAL	(550.29)	(587.98)

Retained earnings

Particulars	31 March 2019	31 March 2018
Opening balance	(587.98)	(606.22)
Profit for the year	37.69	18.24
Closing balance	(550.29)	(587.98)

11.1: Retained earnings represents the cumulative profits of the Company. This Reserve can be utilised in accordance with the provisions of the Companies Act, 2013

13.1. Borrowings

Particulars	31 March 2019	31 March 2018
Current		
Loans from Related Parties		
Unsecured loans		
From Directors	13.87	13.30
TOTAL	13.87	13.30

Net Debt Reconciliation

Particulars	31 March 2019	31 March 2018
Opening Balance of borrowings	13.30	4.79
Add: Amount received during the year	15.11	19.79
Less : Amount repaid during the year	14.54	11.28
Closing balance of borrowings	13.87	13.30

COMBAT DRUGS LIMITED

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

13.2. Trade payables

Particulars	31 March 2019	31 March 2018
Due to Small and medium enterprises	-	-
Due to others	313.40	55.89
TOTAL	313.40	55.89

Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006

Particulars	As at	As at
	31 March 2019	31 March 2018
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	-	-
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	-	-
(iii) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day during the accounting year	-	-
(iv) The amount of interest due and payable for the year	-	-
(v) The amount of interest accrued and remaining unpaid at the end of the accounting year	-	-
(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above are actually paid	-	-

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management.

13.3 Other Financial liabilities

Particulars	31 March 2019	31 March 2018
Expenses Payable	6.04	14.42
TOTAL	6.04	14.42

14. Other current liabilities

Particulars	31 March 2019	31 March 2018
Statutory Liabilities	0.80	0.57
TOTAL	0.80	0.57

Statutory Liabilities include GST, Professional tax, TDS payable

COMBAT DRUGS LIMITED**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019**

All amounts in ₹ Lakhs, unless otherwise stated

15. Revenue from operations

Particulars	31 March 2019	31 March 2018
Sale of products		
Pharma Sales	629.66	50.42
Other Operating Revenue	48.45	51.21
TOTAL	678.11	101.63

15.1: Disaggregated Revenue Disclosures are not applicable to the Company since the Company deals in one product i.e., trading and manufacturing of Pharmaceutical drugs.

15.2: Trade Receivables and Contract Balances

- a) The Company classifies the right to consideration in exchange for deliverables as receivable.
b) A receivable is a right to consideration that is unconditional upon passage of time. Trade receivables are presented net of impairment in the Balance Sheet.

15.3: Disclosures relating to pending performance obligations are not given since there are no pending obligations.

15.4: The impact on account of applying the erstwhile Ind AS - 18 Revenue instead of Ind AS 115 - Revenue from Contracts with Customers on the financial results of the Company for the year ended 31st March, 2019 is insignificant.

16. Other income

Particulars	31 March 2019	31 March 2018
Interest	0.59	0.03
Sundry creditors written back	-	10.90
Foreign Exchange Gain(net)	0.29	0.44
TOTAL	0.88	11.37

17. Cost of materials consumed

Particulars	31 March 2019	31 March 2018
Material Consumed	614.72	43.42
TOTAL	614.72	43.42

18. Changes in inventories of finished goods and stock in trade

Particulars	31 March 2019	31 March 2018
Opening inventories		
Packing materials	4.92	5.72
Finished Goods	4.81	1.31
	(A) 9.73	7.03
Closing inventories		
Packing materials	4.78	4.92
Finished Goods	27.37	4.81
	(B) 32.15	9.73
TOTAL (A-B)	(22.42)	(2.70)

19. Employee benefits expense

Particulars	31 March 2019	31 March 2018
Directors' Remuneration	9.00	9.87
Salaries to Staff	7.48	14.73
ESI contribution	0.04	0.04
Staff welfare expenses	0.16	0.30
TOTAL	16.68	24.94

COMBAT DRUGS LIMITED
STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 March 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Note	31 March 2019	31 March 2018
I. Revenue from operations	15	678.11	101.63
II. Other income	16	0.88	11.37
III. Total revenue (I + II)		678.99	113.00
IV. Expenses			
Cost of materials consumed	17	614.72	43.42
Changes in inventories of finished goods and stock in trade	18	(22.42)	(2.70)
Employee benefits expense	19	16.68	24.94
Depreciation expenses	3	0.06	-
Other expenses	20	32.25	29.10
Total expenses		641.29	94.76
V. Profit/(Loss) before tax (III - IV)		37.70	18.24
VI. Tax expense:			
(1) Current tax		-	-
(2) Deferred tax	12	0.01	-
VII. Profit/(Loss) for the period (V-VI)		37.69	18.24
VIII. Other comprehensive income		-	-
IX. Total comprehensive income for the year		37.69	18.24
X. Earning per equity share (Face Value of Rs. 10/- each)			
(1) Basic		0.47	0.23
(2) Diluted		0.47	0.23

Summary of significant accounting policies

2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For M. Anandam & Co

Chartered Accountants

Firm Registration Number: 000125S

For and on behalf of the Board

Sd/-

A V Sadasiva

Partner

M.No. 018404

Place: Hyderabad

Date: 29.05.2019

Sd/-

Vasudev Kommaraju

Director

DIN: 07233691

Sd/-

Sushant Mohan Lal

Director

DIN: 01227151

COMBAT DRUGS LIMITED
STANDALONE STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Note	Equity share capital
a. Equity share capital		
As at 01 April 2017	10	800
Changes in equity share capital		-
As at 01 April 2018		800
Changes in equity share capital		-
As at 31 March 2019		800

Particulars	Note	Retained Earnings
b. Other equity		
As at 01 April 2017		(606.22)
Profit for the year	11	18.24
As at 01 April 2018		(587.98)
Profit for the year		37.69
As at 31 March 2019		(550.29)

As per our report of even date
 For M. Anandam & Co
 Chartered Accountants
 Firm Registration Number: 0001255
 Sd/-
 A V Sadasiva
 Partner
 M.No. 018404

For and on behalf of the Board

Sd/-
 Vasudev Kommaraju
 Director
 DIN: 07233691

Sd/-
 Sushant Mohan Lal
 Director
 DIN: 01227151

Place: Hyderabad

Date: 29.05.2019

INDEPENDENT AUDITORS' REPORT

To
The Members of Combat Drugs Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Combat Drugs limited (hereafter referred to as "the Parent") and its wholly owned subsidiaries RA Labs PTE Ltd, Singapore and ICP Solutions Private Limited, India (the Parent and its subsidiaries together referred to as 'the Group') comprising of the Consolidated Balance Sheet as at 31st March, 2019, and the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), and the Consolidated Statement of Changes in Equity, and the Consolidated Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of the other auditors on separate financial statements of subsidiaries, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act"), in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Group as at March 31, 2019, and its consolidated profit, consolidated total comprehensive income, consolidated changes in equity and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in sub-

paragraphs (a), (b), (c) &(d) of other matters section below, is sufficient and appropriate to provide a basis for our opinion on the consolidated financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Consolidated financial statements of the current period. These matters were addressed in the context of our audit of the Consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to communicate in our report.

Other Information

The Parent's Board of Directors is responsible for the other information. The other information comprises the information included in the Company's annual report but does not include the consolidated financial statements, standalone financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the other information, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Management's Responsibility for the Consolidated Financial Statements

The Parent's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated total comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the Ind AS and other accounting principles generally accepted in India. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting

policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the parent, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for

expressing our opinion on whether the Parent has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or

regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other matters

We did not audit the financial statements / financial information in respect of the wholly owned subsidiary, RA Labs PTE Ltd, Singapore whose financial statements reflect total assets of Rs.1.68 Lakhs as at 31st March, 2019, total revenue of Rs.0.68 lakhs and net cash outflows/(inflows) amounting to Rs.0.07 Lakhs for the year ended on that date as considered in the consolidated financial statements. The Financial statements has been prepared in accordance with accounting principles generally accepted in its country and which has not been audited and which is certified by the Management. The Management has converted the financial statements of this subsidiary from accounting principles generally accepted in its country to accounting principles generally accepted in India. In our opinion and according to the information and explanations given to us by the Management, these financial results and other financial information are not material to the Group. Our opinion is not modified in respect of this matter.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit as referred to in 'Other Matters' paragraph, we report, to the extent applicable, that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - (b) In our opinion, proper books of account as required by law relating to the preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and returns and reports of the other auditors.
 - (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, Consolidated Statement of Changes in Equity and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of the preparation of the consolidated financial statements.
 - (d) In our opinion, the aforesaid consolidated financial statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act read with Rule 7 of Companies (Accounts) Rules, 2014.

- (e) On the basis of the written representations received from the directors of the Parent and subsidiary company incorporated in India as on 31st March, 2019 taken on record by the Board of Directors of the Parent and subsidiary incorporated in India, none of the directors of the Group Companies incorporated in India is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Parent and subsidiary which is incorporated in India, and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Parent and subsidiary to their respective directors during the year is in accordance with the provisions of section 197 of the Act.

- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Group does not have any pending litigations which would impact its financial position;
 - ii. The Group did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There is no amount required to be transferred to the Investor Education and Protection Fund by the Parent and subsidiary company incorporated in India.

For **M. Anandam & Co.,**
Chartered Accountants
(Firm's Registration No. 000125S)

Sd/-
A.V.Sadasiva
Partner
Membership No. 018404

Place: Hyderabad
Date: 29.05.2019

Annexure - A to the Independent Auditors' Report

(Referred to in paragraph 1(f) under 'Report on Other Legal Regulatory Requirements' section of our report to the Members of Combat Drugs Limited of even date)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Combat Drugs Limited ("the Parent") and its subsidiary, which is incorporated in India, as of 31 March 2019 in conjunction with our audit of the consolidated financial statements of the Group for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Parent, its subsidiary company incorporated in India are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Parent considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Parent's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial

controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the parent and its subsidiary company which is incorporated in India.

Meaning of Internal Financial Controls over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls

over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us the Parent and its subsidiary company, which are companies incorporated in India, have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Parent considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **M. Anandam & Co.,**
Chartered Accountants
(Firm's Registration No. 000125S)

Sd/-

A.V.Sadasiva

Partner

Membership No. 018404

Place: Hyderabad

Date: 29.05.2019

COMBAT DRUGS LIMITED
CONSOLIDATED BALANCE SHEET AS AT 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Note	31 March 2019	31 March 2018
I. ASSETS			
Non-current Assets			
(a) Property, Plant and Equipment	3	0.70	-
(b) Other non-current assets	4	1.82	0.30
Current Assets			
(a) Inventories	5	32.15	9.73
(b) Financial assets			
(i) Trade receivables	6.1	345.67	58.78
(ii) Cash and cash equivalents	6.2	29.97	2.29
(c) Other current assets	7	223.89	225.10
TOTAL ASSETS		634.20	296.20
II. EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	8	800.00	800.00
(b) Other equity	9	(547.34)	(587.98)
Liabilities			
Current Liabilities			
(a) Financial liabilities			
(i) Borrowings	10.1	20.08	13.30
(ii) Trade payables	10.2		
a) Total outstanding dues of Micro enterprises and small enterprises		-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises		313.40	55.89
(iii) Other Financial liabilities	10.3	42.56	14.42
(b) Other current liabilities	11	1.96	0.57
(c) Current Tax Liabilities (net)	12	3.54	-
TOTAL EQUITY AND LIABILITIES		634.20	296.20

Summary of significant accounting policies

2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For M. Anandam & Co

For and on behalf of the Board

Chartered Accountants

Firm Registration Number: 0001255

Sd/-

Sd/-

Sd/-

A V Sadasiva

Vasudev Komaraju

Sushant Mohan Lal

Partner

Wholetime Director

Director

M.No. 018404

DIN: 07233691

DIN: 01227151

Place: Hyderabad

Date: 29.05.2019

COMBAT DRUGS LIMITED
CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Note	Year ended 31 March 2019	Year ended 31 March 2018
I. Revenue from operations	13	805.78	101.63
II. Other income	14	-	11.37
III. Total revenue (I + II)		805.78	113.00
IV. Expenses			
Cost of materials consumed	15	614.72	43.42
Changes in inventories of finished goods and stock in trade	16	(22.42)	(2.70)
Depreciation	3	0.06	-
Employee benefits expense	17	109.73	24.94
Other expenses	18	59.61	29.10
Total expenses		761.70	94.76
V. Profit/Loss before tax (III - IV)		44.08	18.24
VI. Tax expense:			
(1) Current tax	12	3.54	-
(2) Deferred tax		-	-
VII. Profit/Loss for the period (V-VI)		40.54	18.24
VIII. Other comprehensive income			
Items that will be reclassified to statement of profit and loss			
Exchange differences on translating the financial statements of a foreign operation		0.10	-
Other comprehensive income (net of tax)		0.10	-
VIII. Total comprehensive income for the year		40.64	18.24
Net Profit for the year attributable to:			
Owners of the parent		40.54	18.24
Non-Controlling Interests		-	-
Other Comprehensive Income attributable to:			
Owners of the parent		0.10	-
Non-Controlling Interests		-	-
Total Comprehensive Income attributable to:			
Owners of the parent		40.64	18.24
Non-Controlling Interests		-	-
IX. Earning per equity share attributable to the owners of Combat Drugs Limited	25		
(1) Basic		0.51	0.23
(2) Diluted		0.51	0.23

Summary of significant accounting policies

2

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For M. Anandam & Co
Chartered Accountants
Firm Registration Number: 0001255

For and on behalf of the Board

A V Sadasiva
Partner
M.No. 018404
Place: Hyderabad
Date: 29.05.2019

Sd/-
Vasudev Komaraju
Wholetime Director
DIN: 07233691

Sd/-
Sushant Mohan Lal
Director
DIN: 01227151

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

1. Background

Combat Drugs Limited was incorporated in 1986 having its registered office in Hyderabad. The Group deals in trading, manufacturing of Pharmaceutical drugs and consultancy services.

These Financial Statements of the Group as at and for the year ended 31st March, 2019 (including comparatives) were approved and authorised for issue by the Board of Directors of the Group on 29th May, 2019.

The Group includes the following wholly owned subsidiaries, viz, RA Labs Pte Ltd, Singapore and ICP Solutions Private Limited, India.

2. Significant Accounting Policies

This note provides a list of the significant accounting policies adopted in the preparation of the financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

a) Statement of Compliance

The financial statements are prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Amendment Rules, 2016 and Companies (Indian Accounting Standards) Amendment Rules, 2017, the relevant provisions of the Companies Act, 2013 ('the Act') and guidelines issued by the Securities and Exchange Board of India (SEBI), as applicable.

b) Basis of preparation

The financial statements have been prepared under the historical cost convention with the exception of certain assets and liabilities that are required to be carried at fair values by Ind AS. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

c) Use of estimates and critical accounting judgements

In preparation of the financial statements, the Group makes judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and the associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and the underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and future periods affected.

Significant judgements and estimates relating to the carrying values of assets and liabilities include useful lives of property, plant and equipment and intangible assets, impairment of property, plant and equipment, intangible assets and investments, provision for employee benefits and other provisions, recoverability of deferred tax assets, commitments and contingencies.

d) Revenue Recognition

i) Sale of products

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Group and the amount can be reliably measured. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, usually on delivery / dispatch of the goods. Revenue from the sale of goods is measured at the value of the consideration received or receivable, net of returns, discounts, volume rebates. Till 30th June 2017, Revenue is inclusive of excise duty and excluding taxes collected from parties such as outgoing sales taxes or value added taxes. With effect from 1st July, 2017 revenue is excluding goods and service tax.

ii) Sale of services

Revenue is recognised upon transfer of control of promised products or services to customers in an amount that reflects the consideration which the Company expects to receive in exchange for those products or services.

- Revenue from fixed price development contracts is recognised on output basis measured by units delivered, efforts expended, number of transactions processed, etc.
- Revenue related to fixed price maintenance and support services contracts where the Company is standing ready to provide services is recognised based on time elapsed mode and revenue is straight lined over the period of performance.

Unbilled Revenue on incomplete service contracts are estimated based on the extent of completion.

Contract assets are recognised when there is excess of revenue earned over billings on contracts. Contract assets are classified as unbilled receivables (only act of invoicing is pending) when there is unconditional right to receive cash, and only passage of time is required, as per contractual terms.

iii) Other income

Dividend income is recognised when the shareholder's right to receive the income is established.

Interest income is recognized on time proportion basis taking into account the amount outstanding and the rate applicable.

e) Income tax

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in the countries where the Group operates and generates taxable income.

Current income tax relating to items recognised outside profit or loss is recognised in outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date.

Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Deferred tax assets and deferred tax

liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

f) Impairment of assets

Property, plant and equipment and intangible assets are tested for impairment annually whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

g) Cash and cash equivalents

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

h) Trade receivables

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using effective interest method, less provision for impairment.

i) Inventories

Raw Materials, Fuel, Stores & Spares and Packing Materials Valued at lower of cost and net realizable value (NRV). However, these items are considered to be realizable at cost, if the finished products, in which they will be used, are expected to be sold at or above cost, Cost is determined on weighted Average basis.

Work-in-Progress (WIP) and Finished Goods

Valued at lower of cost and NRV. Cost of Finished Goods and WIP includes cost of raw materials, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Cost of inventories is computed on weighted average basis

j) **other financial assets**

i) **Classification**

The Group classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through profit or loss), and
- those measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in Statement of profit or loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for equity investment at fair value through other comprehensive income.

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

ii) **Measurement**

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in profit or loss.

Amortised cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost.

Fair value through other comprehensive income (FVOCI): Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognised in profit and loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss and recognised in other gains/(losses). Interest income from these financial assets is included in other income using the effective interest rate method.

Fair value through profit or loss: Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the statement of profit and loss in the period in which it arises. Interest income from these financial assets is included in other income.

Equity instruments:

The Group subsequently measures all equity investments at fair value. Where the Group's management has elected to present fair value gains and losses on equity investments in other comprehensive income, there is no subsequent reclassification of fair value gains and losses to profit or loss. Dividends from such investments are recognised in profit or loss as other income when the Group's right to receive payments is established.

Changes in the fair value of financial assets at fair value through profit or loss are recognised in the other income. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

iii) Impairment of financial assets

The Group assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost and FVOCI debt instruments. The impairment methodology applied depends on whether there has been a significant increase in credit risk. Note 20 details how the Group determines whether there has been a significant increase in credit risk.

For trade receivables only, the Group applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

iv) Derecognition of financial assets

A financial asset is derecognized only when

- The Group has transferred the rights to receive cash flow from the financial asset or
- retains the contractual rights to receive the cash flows of the financial assets, but assumes a contractual obligation to pay cash flows to one or more recipients.

Where the entity has transferred an asset, the Group evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is derecognized. Where the entity has not transferred substantially all risks and rewards of ownership of the financial asset is not derecognized.

Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is derecognised if the Group has not retained control of the financial asset. Where the Group retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

k) Offsetting financial instruments

Financial assets and liabilities are offset and the net amount is reported in the balance sheet where there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Group or the counterparty.

l) Property, plant and equipment

Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Depreciation/Amortisation methods, estimated useful lives and residual value Depreciation is calculated using the straight-line basis at the rates arrived at based on the useful lives prescribed in Schedule II of the Companies Act, 2013. The Group follows the policy of charging depreciation on pro-rata basis on the assets acquired or disposed off during the year. Leasehold assets are amortised over the period of lease.

The residual values are not more than 5% of the original cost of the asset. The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains or losses on disposal are determined by comparing proceeds with carrying amount.

m) Trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of financial year which are unpaid. The amounts are unsecured and are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.

n) Borrowings

Borrowings are initially recognized at fair value, net of transaction cost incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognized as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent there is no evidence that it is probable that some or all the facility will be drawn down, the fee is capitalized as a prepayment for liquidity services and amortized over the period of the facility to which it relates.

Borrowings are removed from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

Where the terms of a financial liability are renegotiated and the entity issues equity instruments to a creditor to extinguish all or part of the liability (debt for equity swap), a gain or loss is recognized in profit or loss, which is measured as the difference between the carrying amount of the financial liability and the fair value of the equity instrument issued.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period. Where there is a breach of a material provision of a long-term loan arrangement on or before the end of the reporting period with the effect that the liability becomes payable on demand on the reporting date, the entity does not classify the liability as current, if the lender agreed, after the reporting period and before the approval of financial statements for issue, not to demand payment as consequence of the breach.

o) Borrowing costs

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized

during the period of time that is required to complete and prepare the asset for its intended use or sale

Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing cost eligible for capitalization.

Other borrowings costs are expensed in the period in which they are incurred.

p) Provisions

Provisions for legal claims and returns are recognised when the Group has a present legal or constructive obligation as a result of past event, it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are not recognised for future operating losses.

Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provisions due to the passage of time is recognized as interest expense.

q) Employee benefits

Short-term obligations

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

r) Contributed equity

Equity shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

s) Dividends

Provision is made for the amount of any dividend declared, being appropriately authorized and no longer at the discretion of the entity, on or before the end of the reporting period but not distributed at the end of the reporting period.

t) Earning per share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- The profit attributable to owners of the Group
- By the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares.

(ii) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- The after income tax effect of interest and other financing costs associated with dilutive potential equity shares, and
- The weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

u) Segment Reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker.

v) Rounding of amounts

All amounts disclosed in the financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Schedule III, unless otherwise stated.

w) Recent accounting pronouncements

- a) Ind AS 116 Leases: On March 30, 2019, Ministry of Corporate Affairs has notified Ind AS 116, Leases. Ind AS 116 will replace the existing leases Standard, Ind AS 17 Leases, and related Interpretations. The Standard sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract i.e., the lessee and the lessor.

Ind AS 116 introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for all leases with a term of more than twelve months, unless the underlying asset is of low value. Currently, operating lease expenses are charged to the statement of Profit and Loss. The Standard also contains enhanced disclosure requirements for lessees. Ind AS 116 substantially carries forward the lessor accounting requirements in Ind AS 17.

The effective date for adoption of Ind AS 116 is annual periods beginning on or after April 1, 2019. The standard permits two possible methods of transition:

- Full retrospective – Retrospectively to each prior period presented applying Ind AS 8 Accounting Policies, Changes in Accounting Estimates and Errors
- Modified retrospective – Retrospectively, with the cumulative effect of initially applying the Standard recognized at the date of initial application.

Under modified retrospective approach, the lessee records the lease liability as the present value of the remaining lease payments, discounted at the incremental borrowing rate and the right of use asset either as:

- Its carrying amount as if the standard had been applied since the commencement date, but discounted at lessee ' s incremental borrowing rate at the date of initial application or
- An amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments related to that lease recognized under Ind AS 17 immediately before the date of initial application.

Certain practical expedients are available under both the methods. There is no impact on the financial statements on account of this amendment as Group does not have any lease transaction.

b) Ind AS 12 Appendix C, Uncertainty over Income Tax Treatments:

On March 30, 2019, Ministry of Corporate Affairs has notified Ind AS 12 Appendix C, Uncertainty over Income Tax Treatments which is to be applied while performing the determination of taxable profit (or loss), tax bases, unused tax losses, unused tax credits and tax rates, when there is uncertainty over income tax treatments under Ind AS 12. According to the appendix, companies need to determine the probability of the relevant tax authority accepting each tax treatment, or group of tax treatments, that the companies have used or plan to use in their income tax filing which has to be considered to compute the most likely amount or the expected value of the tax treatment when determining taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates. The standard permits two possible methods of transition - i) Full retrospective approach – Under this approach, Appendix C will be applied retrospectively to each prior reporting period presented in accordance with Ind AS 8 – Accounting Policies, Changes in Accounting Estimates and Errors, without using hindsight and ii) Retrospectively with cumulative effect of initially applying Appendix C recognized by adjusting equity on initial application, without adjusting comparatives.

The effective date for adoption of Ind AS 12 Appendix C is annual periods beginning on or after April 1, 2019. The Group will adopt the standard on

April 1, 2019 and has decided to adjust the cumulative effect in equity on the date of initial application i.e. April 1, 2019 without adjusting comparatives.

The effect on adoption of Ind AS 12 Appendix C would be insignificant in the standalone financial statements.

c) Amendment to Ind AS 12 – Income taxes :

On March 30, 2019, Ministry of Corporate Affairs issued amendments to the guidance in Ind AS 12, ' Income Taxes ', in connection with accounting for dividend distribution taxes.

The amendment clarifies that an entity shall recognise the income tax consequences of dividends in profit or loss, other comprehensive income or equity according to where the entity originally recognised those past transactions or events.

Effective date for application of this amendment is annual period beginning on or after April 1, 2019. The Group is currently evaluating the effect of this amendment on the financial statements.

d) Amendment to Ind AS 19 –

Plan amendment, curtailment or settlement- On March 30, 2019, Ministry of Corporate Affairs issued amendments to Ind AS19, 'Employee Benefits', in connection with accounting for plan amendments, curtailments and settlements.

The amendments require an entity:

- to use updated assumptions to determine current service cost and net interest for the remainder of the period after a plan amendment, curtailment or settlement; and
- to recognise in profit or loss as part of past service cost, or a gain or loss on settlement, any reduction in a surplus, even if that surplus was not previously recognised because of the impact of the asset ceiling.

Effective date for application of this amendment is annual period beginning on or after April 1, 2019. There is no impact on the financial statements on account of this amendment.

Notes to the financial statements for the year ended 31st March, 2019

3 Property, Plant and Equipment

Changes in the carrying value property, plant and equipment for the year ended 31st March, 2019

All amounts in ₹ Lakhs, unless otherwise stated

Sr. No	Particulars	Plant and Equipment	Computers	Total
1	Gross Carrying Amount			
	As at 1st April, 2018	-	-	-
	Additions	0.41	0.18	0.59
	Disposal / Adjustments	-	-	-
	As at 31st March, 2019	0.41	0.18	0.59
2	Depreciation			
	As at 1st April, 2018	-	-	-
	Charge for the year	0.06	-	0.06
	Disposal / Adjustments	-	-	-
	As at 31st March, 2019	0.06	-	0.06
3	Net Block			
	As at 31st March, 2019	0.35	0.18	0.53

3.1 Other Intangible Assets - Computer Software

Changes in the carrying value other intangible assets for the year ended 31st March, 2019

Sr. No	Particulars	Rs. In Lakh
1	Gross Carrying Amount	
	As at 1st April, 2018	-
	Additions	0.17
	As at 31st March, 2019	0.17
2	Amortisation	
	As at 1st April, 2018	-
	Charge for the year	-
	As at 31st March, 2019	-
3	Net Block	
	As at 31st March, 2019	0.17

COMBAT DRUGS LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

4. Other Non-Current assets

Particulars	31 March 2019	31 March 2018
a) Deposit - Rent	0.30	0.30
b) Deposits with Department	1.52	-
TOTAL	1.82	0.30

5. Inventories (Valued at Lower of Cost and NRV, Unless otherwise stated)

Particulars	31 March 2019	31 March 2018
a) Packing Material	4.78	4.92
b) Finished goods	27.37	4.81
TOTAL	32.15	9.73

6.1 . Trade receivables

Particulars	31 March 2019	31 March 2018
Trade Receivables considered good - Unsecured	345.67	58.78
TOTAL	345.67	58.78

6.2. Cash and cash equivalents

Particulars	31 March 2019	31 March 2018
a) Balances with banks in current accounts	29.24	2.28
b) Cash on hand	0.73	0.01
TOTAL	29.97	2.29

7. Other current assets

Particulars	31 March 2019	31 March 2018
Advances to Suppliers	-	0.11
Others	-	0.04
Deposit with others	221.39	222.89
Input Tax Receivables	2.50	2.06
TOTAL	223.89	225.10

8. Equity share capital

Particulars	31 March 2019	31 March 2018
AUTHORIZED:		
8,000,000 Equity Shares of ₹10/- each (P Y 80,00,000 Equity Shares of ₹10/- each)	800.00	800.00
TOTAL	800.00	800.00
ISSUED, SUBSCRIBED & PAID-UP CAPITAL		
80,00,000 Equity Shares of ₹10/- each (P Y 80,00,000 Equity Shares of ₹10/- each)	800.00	800.00
TOTAL	800.00	800.00

COMBAT DRUGS LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

(A) Movement in equity share capital:

Particulars	Number of shares	Total
Balance at April 01, 2018	80,00,000	800
Movement during the year	-	-
Balance at March 31, 2019	80,00,000	800

(B) Details of shareholders holding more than 5% shares in the Company

Name of the shareholder	31 March 2019		31 March 2018	
	No. of Shares	% holding	No. of Shares	% holding
Janakiram Ajarapu	46,39,927	58.00	46,39,927	58.00
Sushant Mohan Lal	6,55,200	8.19	6,55,200	8.19

(C) Terms/Rights attached to equity shares

The Company has only one class of equity shares having a face value of ₹ 10 /- each. Each holder of equity share is entitled to one vote per share. The company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation of the company, the equity shareholders will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(D) The Company has not issued any share as fully paid up without payment being received in cash or as bonus shares nor any share has been bought back by the Company since its incorporation.

9. Other equity

Particulars	31 March 2019	31 March 2018
Reserves and surplus		
Retained earnings	(547.44)	(587.98)
Other Comprehensive Income		
Exchange differences in translating the financial statements of foreign operations	0.10	-
TOTAL	(547.34)	(587.98)

(a) Retained earnings

Particulars	31 March 2019	31 March 2018
Opening balance	(587.98)	(606.22)
Profit/(Loss) for the year	40.54	18.24
Closing balance	(547.44)	(587.98)

(b) Exchange differences in translating the financial statements of foreign operations

Particulars	31 March 2019	31 March 2018
Opening balance	-	-
Movement during the year	0.10	-
Closing balance	0.10	-

10.1 Borrowings

Particulars	31 March 2019	31 March 2018
Current		
Loans from Related Parties		
Unsecured loans		
From Directors	20.08	13.30
TOTAL	20.08	13.30

10.2. Trade payables

Particulars	31 March 2019	31 March 2018
Dues to micro enterprises and small enterprises	-	-
Dues to creditors other than micro enterprises and small enterprises	313.40	55.89
TOTAL	313.40	55.89

COMBAT DRUGS LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006

Dues to creditors other than micro enterprises and small enterprises	31 March 2019	31 March 2018
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year		
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year		
(iii) The amount of interest paid along with the amounts of the payment made to the supplier		
(iv) The amount of interest due and payable for the year		
(v) The amount of interest accrued and remaining unpaid at the end of the accounting year		
(vi) The amount of further interest due and payable even in the succeeding year, until such		

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management.

10.3 Other Financial liabilities

Paticulars	31 March 2019	31 March 2018
Expenses payable	42.56	14.42
TOTAL	42.56	14.42

11. Other current liabilities

Paticulars	31 March 2019	31 March 2018
Statutory Liabilities	1.96	0.57
TOTAL	1.96	0.57

12. Current Tax Liability

Paticulars	31 March 2019	31 March 2018
Provision for Tax	3.54	-
TOTAL	3.54	-

COMBAT DRUGS LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

13. Revenue from operations

Particulars	31 March 2019	31 March 2018
Sale of products		
Pharma Sales	629.66	50.42
Sale of Services		
IT Consulting Services	176.12	51.21
TOTAL	805.78	101.63

14. Other income

Particulars	31 March 2019	31 March 2018
Sundry creditors written back	-	10.90
Foreign Exchange Gain(net)	-	0.44
Discount Received	-	0.03
TOTAL	-	11.37

15. Cost of materials consumed

Particulars	31 March 2019	31 March 2018
Material consumed	614.72	43.42
TOTAL	614.72	43.42

16. Changes in inventories of finished goods, work in progress and traded goods

Particulars	31 March 2019	31 March 2018
Opening inventories		
Packing materials	4.92	5.72
Finished Goods	4.81	1.31
	(A) 9.73	7.03
Closing inventories		
Packing materials	4.78	4.92
Finished Goods	27.37	4.81
	(B) 32.15	9.73
TOTAL (A-B)	(22.42)	(2.70)

17. Employee benefits expense

Particulars	31 March 2019	31 March 2018
Salaries to Staff	100.33	14.73
Directors' Remuneration	9.00	9.87
Contribution to PF and ESI	0.24	0.04
Staff welfare expenses	0.16	0.30
TOTAL	109.73	24.94

COMBAT DRUGS LIMITED**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019**

All amounts in ₹ Lakhs, unless otherwise stated

18. Other expenses

Particulars	31 March 2019	31 March 2018
Advertisement Expenses	0.56	0.73
Payment to Auditor (Refer Note 18a)	1.91	1.06
Consultancy & Other Charges	17.23	4.07
Travelling Expenses	1.75	2.89
Office Expenses	1.43	0.87
Postage & Telegrams	5.20	2.90
Printing & Stationery	1.90	1.11
Rent, Rates and Taxes	15.80	2.87
Telephone Expenses	0.28	0.34
Listing Fee	2.50	3.13
Balances written off	-	8.93
Water charges	0.12	-
Security Charges	0.15	-
Electricity and generator expenses	1.70	-
Preliminary expenses written off	2.36	-
Forex loss	1.08	-
Bank Charges	0.62	-
Miscellaneous Expenses	5.02	0.20
TOTAL	59.61	29.10

18a. Payment to auditor

Particulars	31 March 2019	31 March 2018
To statutory auditors		
-Statutory audit fee	0.70	0.50
-Tax Audit fee	0.20	0.10
-For other services (including fees for quarterly reviews)	1.01	0.46
TOTAL	1.91	1.06

COMBAT DRUGS LIMITED

Notes to Consolidated Financial Statements for the year ended 31 March, 2019

All amounts in ₹ Lakhs, unless otherwise stated

19. Segment information**a) Description of segments and principal activities**

The Group primarily operates in the Pharmaceutical segment, IT Consultancy Services and others. The Chief Operating Decision Maker (CODM) reviews the performance of the above mentioned segments at the consolidated level and makes decisions on sales volumes and profit ability.

b) Major Customer in group

93% of Revenue is coming from two customers.

18. Additional information, as required under Schedule III to The Companies Act, 2013

Statement of Net Assets, Profit and Loss and other comprehensive income attributable to owners and non-controlling interest						
Name of the Entity	Net Assets, i.e. Total Assets minus Total Liabilities		Share in profit and loss		Share in Other Comprehensive Income	Share in Total Comprehensive Income
	As a % of consolidated Net assets	Amount	As a % of consolidated Profit and Loss	Amount	As a % of consolidated Other Comprehensive Income	As a % of consolidated Total Comprehensive Income
Parent						
Combat Drugs Limited - Parent Company	97.02	245.13	91.50	37.09	-	91.26
Subsidiary						
ICP Solutions Private Limited	3.37	8.52	19.93	8.08	-	19.88
RA LABS Pte Ltd, Singapore	(0.39)	(0.99)	(11.43)	(4.63)	100.00	(11.15)
TOTAL	100.00	252.66	100.00	40.54	100.00	100.00
						40.64

COMBAT DRUGS LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

20. Financial instruments and risk management

Fair values

- The carrying amounts of trade payables, other financial liabilities(current), borrowings (current),trade receivables, cash and cash equivalents, other bank balances and loans are considered to be the same as fair value due to their short term nature.
- Borrowings(non-current) consists of loans from banks and government authorities, other financial liabilities(non-current) consists of interest accrued but not due on deposits other financial assets consists of employee advances where the fair value is considered based on the discounted cash flow.
- The fair value of forward foreign exchange contracts is calculated as the present value determined using forward exchange rates, currency basis spreads between the respective currencies and interest rate curves.

The fair value of financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

Set out below, is a comparison by class of the carrying amounts and fair value of the Group's financial instruments, other than those with carrying amounts that are reasonable approximation of fair values:

(i) Categories of financial instruments

Particulars	Level	31 March 2019		31 March 2018	
		Carrying amount	Fair value*	Carrying amount	Fair value*
Financial assets					
Measured at amortised cost:					
Current					
Trade receivables	3	345.67	345.67	58.76	58.76
Cash and Cash Equivalents	3	29.97	29.97	2.29	2.29
Total		375.64	375.64	61.07	61.07
Financial liabilities					
Measured at amortised cost					
Current					
Borrowings	3	20.08	20.08	13.30	13.30
Trade Payables	3	313.40	313.40	55.89	55.89
Other Financial liabilities	3	42.56	42.56	14.42	14.42
Total		376.04	376.04	83.61	83.61

*Fair value of instruments is classified in various fair value hierarchies based on the following three levels:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques, which maximise the use of observable market data and rely as little as possible on entity specific estimates. If significant inputs required to fair value an instrument are observable, the instrument is included in Level 2.

Level 3: If one or more of the significant inputs are not based on observable market data, the instruments is included in level 3.

Management uses its best judgement in estimating the fair value of its financial instruments. However, there are inherent limitations in any estimation technique. Therefore, for substantially all financial instruments, the fair value is not necessarily the same as the carrying amount. Current carrying amounts are used for the purpose of the consolidated financial statements as at the transaction date, the fair value of financial instruments subsequent to the reporting dates may be different from the amounts reported at each reporting date. In respect of investments as at the transaction date, the Group has assessed the fair value to be the carrying value of the investments as these companies are in their initial years of operations obtaining necessary regulatory approvals to commence their business.

21. Financial risk management

The Group is exposed to market risk (fluctuation in foreign currency exchange rates, price and interest rates), liquidity risk and credit risk, which may adversely impact the fair value of its financial instruments. The Group assesses the unpredictability of the financial environment and seeks to mitigate potential adverse effects on the financial performance of the Group.

(A) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of currency risk, interest rate risk and price risk. Financial instruments affected by market risk include loans and borrowings, trade receivables and trade payables involving foreign currency exposure. The sensitivity analyses in the following sections relate to the position as at March 31, 2019 and March 31, 2018.

The analysis exclude the impact of movements in market variables on the carrying values of financial assets and liabilities.

The sensitivity of the relevant profit or loss item is the effect of the assumed changes in respective market risks. This is based on the financial assets and financial liabilities held at 31 March 2019 and 31 March 2018.

(i) Foreign currency exchange rate risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the trade/other payables, trade/other receivables and derivative assets/liabilities. The risks primarily relate to fluctuations in US Dollar against the Singapore Dollar. The Group is also exposed to foreign currency changes for all other currencies is not material. The Group evaluates the impact of foreign exchange rate fluctuations by assessing its exposure to exchange rate risks.

The following tables demonstrate the sensitivity to a reasonably possible change in US dollars rates with all other variables held constant. The impact on the Group's profit before tax is due to changes in the fair value of monetary assets and liabilities.

(ii) Sensitivity

The sensitivity of profit or loss to changes in the exchange rates arises mainly from foreign currency denominated financial instruments and from foreign forward exchange contracts:

Particulars	Increase/(decrease) in profit before tax		Increase/(decrease) in other components of equity		Increase/(decrease) in other components of equity	
	31 March 2019	31 March 2018	31 March 2019	31 March 2018	31 March 2018	31 March 2018
Change in USD						
1% increase	0.71	0.25	0.71	0.71	0.23	0.23
1% decrease	(0.71)	(0.25)	(0.71)	(0.23)		
1% increase	0.03	0.04	0.03	0.04	0.04	0.04
1% decrease	(0.03)	(0.04)	(0.03)	(0.04)	(0.04)	(0.04)

The movement in the pre-tax effect is a result of a change in the fair value of monetary assets and liabilities denominated in US dollars where the functional currency of the group is a currency other than US dollars.

(b) Credit Risk

Credit risk is the risk arising from credit exposure to customers, cash and cash equivalents held with banks and current and non-current held to maturity financial assets.

With respect to credit exposure from customers, the Group has a procedure in place aiming to minimise collection losses. Credit Control team assesses the credit quality of the customers, their financial position, past experience in payments and other relevant factors. Cash and other collaterals are obtained from customers when considered necessary under the circumstances.

The carrying amount of trade receivables, loans, advances, deposits, cash and bank balances, bank deposits and interest receivable on deposits represent the Group's maximum exposure to the credit risk. No other financial assets carry a significant exposure with respect to the credit risk. Bank deposits and cash balances are placed with reputable banks and deposits are with reputable government, public bodies and others.

The credit quality of financial assets is satisfactory, taking into account the allowance for credit losses.

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including default risk associate with the industry and country in which customers operate. Credit quality of a customer is assessed based on an extensive credit rating scorecard and individual credit limits are defined in accordance with this assessment.

An impairment analysis is performed at each reporting date on an individual basis for major receivables. In addition, a large number of minor receivables are grouped into homogenous groups and assessed for impairment collectively. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets. The Group also holds deposits as security from certain customers to mitigate credit risk.

i. Credit risk on cash and cash equivalents and other bank balances is limited as the Group generally invest in deposits with banks with high credit ratings assigned by external agencies.

COMBAT DRUGS LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

ii. Credit risk on trade receivables and other financial assets is evaluated as follows:

(i) Expected credit loss for trade receivable under simplified approach:

Particulars	31 March 2019	31 March 2018
Gross carrying amount	345.67	58.78
Expected credit losses (Loss allowance provision)	-	-
Carrying amount of trade receivables	345.67	58.78

(ii) Reconciliation of loss allowance provision

Particulars	Trade receivables
Loss allowance as at 31 March 2018	-
Changes in loss allowance during the period of 2018-19	-
Loss allowance as at 31 March 2019	-

(iii) Significant estimates and judgements impairment of financial assets:

The impairment provisions for financial assets disclosed above are based on assumptions about risk of default and expected loss rates. The Group uses judgement in making these assumptions and selecting the inputs to the impairment calculation, based on the Group's past history, existing market conditions as well as forward looking estimates at the end of each reporting period.

(C) Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and the availability of funding to meet obligations when due and to dose out market positions. Group's treasury maintains flexibility in funding by maintaining availability under deposits in banks.

Management monitors cash and cash equivalents on the basis of expected cash flows.

(ii) Maturities of Financial liabilities

Contractual maturities of financial liabilities as at:

Particulars	31 March 2019		31 March 2018	
	Less than 12 months	More than 12 months	Less than 12 months	More than 12 months
Borrowings	20.08	-	13.30	-
Trade Payables	313.40	-	55.89	-
Expenses Payable	42.56	-	14.42	-
Total	376.04	-	83.61	-

22. Capital management

A. Capital management and Gearing Ratio

For the purpose of the Group's capital management, capital includes issued equity capital and all other equity reserves attributable to the equity holders. The primary objective of the Group's capital management is to maximise the shareholder value.

The Group manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. The Group monitors capital using a gearing ratio, which is debt divided by total capital. The Group includes within debt, interest bearing loans and borrowings.

Particulars	31 March 2019	31 March 2018
Borrowings		
Current	20.08	13.30
Debt	20.08	13.30
Equity		
Equity share capital	800.00	800.00
Other equity	(547.34)	(587.98)
Total capital	252.66	212.02
Gearing ratio in % (Debt/ Capital)	7.95%	6.27%

In order to achieve this overall objective, the Group's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings.

No changes were made in the objectives, policies or processes for managing capital during the years ended 31 March 2019 and 31 March 2018.

COMBAT DRUGS LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

23. Contingent liabilities and Capital Commitments- Nil

24. Related party transactions

Names of related parties and nature of relationships:

Names of the related parties	Nature of relationship
i) Key Management Personnel (KMP): Sushanth Mohan Lal Vemuri Shilpa Ragu Raghuram Vasudev Komaraju Kumar Raghavan Sonam Jalan	Director Independent Director Independent Director Director Company Secretary from 20/12/2018 Chief Financial Officer from 27/03/2019
ii) Relatives of Key Management Personnel (KMP): Suchit Mohan Lal Ruchi Bio Tech	Father of Sushanth Mohan Lal Sushanth Mohan Lal - Proprietor

Names of the related parties	Nature of Transactions	31 March 2019	31 March 2018
Suchit Mohan Lal	Remuneration	-	4.50
Sushanth Mohan Lal	Remuneration	9.00	5.37
Suchit Mohan Lal	Unsecured loans repaid(Net)	3.53	0.47
Sushanth Mohan Lal	Unsecured loans taken(Net)	10.31	8.98

Details of outstanding balances as at the year end where related party relationship existed:

Names of the related parties	Nature of Balance	31 March 2019	31 March 2018
Suchit Mohan Lal	Unsecured loans taken	-	3.53
Sushanth Mohan Lal	Unsecured loans taken	20.08	9.77

25. Earnings per share (EPS)

Particulars	31 March 2019	31 March 2018
Profit after tax	40.54	18.24
Weighted average number of equity shares in calculating Basic and Diluted EPS (in Numbers)	80,00,000	80,00,000
Face value per share ₹	10.00	10.00
Basic and Diluted Earnings per Share (EPS)₹	0.51	0.23

26. Previous Year figures have been regrouped wherever necessary.

As per our report of even date
For: M. Anandam & Co
Chartered Accountants
Firm Registration Number: 0001255

Sd/-
A V Sadasiva
Partner
M.No. 018404

Place: Hyderabad
Date: 29.05.2019

For and on behalf of the Board

Sd/-
Vasudev Komaraju
Wholetime Director
DIN: 07233691

Sd/-
Sushant Mohan Lal
Director
DIN: 01227151

COMBAT DRUGS LIMITED

Cash Flow Statement for the year ended 31st March, 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Year ended	
	31st March, 2019	31st March, 2018
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	44.08	18.24
Adjustments for :		
Depreciation and Amortization Expense	0.06	-
Operating Profit before Working Capital Changes	44.14	18.24
Adjustments for:		
(Increase) / Decrease in Trade Receivables	(286.89)	(45.25)
(Increase) / Decrease in Inventories	(22.42)	7.92
(Increase) / Decrease in Other Assets	1.21	(2.70)
Increase / (Decrease) in Trade Payable	257.51	9.72
Increase / (Decrease) in Other Liabilities	29.53	2.39
	(21.06)	(27.92)
Cash Generated from Operations	23.08	(9.68)
Direct Taxes Paid	-	-
Net Cash generated from/(used in) Operating Activities	23.08	(9.68)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant & Equipment	(0.76)	-
Deposits with departments	(1.52)	-
Net Cash used in Investing Activities	(2.28)	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (Repayment) of Short Term Borrowings (net)	6.78	8.51
Net Cash generated from Financing Activities	6.78	8.51
Net decrease in Cash and Cash Equivalents	27.58	(1.17)
Cash and Cash Equivalents at the beginning of the year	2.29	3.46
Cash and Cash Equivalents at the end of the year	29.87	2.29

Notes to cash flow statement

1 Components of cash and cash equivalents

Balances with banks	29.24	2.28
Cash on hand	0.73	0.01
Cash and cash equivalents considered in the cash flow statement	29.97	2.29

2 The above cash flow statement has been prepared under with the 'Indirect method' as set out in Indian Accounting Standard - 7 Statement of Cash Flows.

3 Reconciliation of liabilities arising from financing activities.

Particulars	Outstanding as at 1st April, 2018	Cash flows	Non-cash Changes	Outstanding as at 31st March, 2019
Short-term borrowings - Directors	13.30	6.78	-	20.08
Total liabilities from financing activities	13.30	6.78	-	20.08

Significant Accounting Policies

Note 2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For M. Anandam & Co

Chartered Accountants

Firm Registration Number: 0001255

Sd/-

A V Sadasiva

Partner

M.No. 018404

Sd/-

Vasudev Komaraju

Wholetime Director

DIN: 07233691

Sd/-

Sushant Mohan Lal

Director

DIN: 01227151

Place: Hyderabad

Date: 29.05.2019

COMBAT DRUGS LIMITED
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2019

All amounts in ₹ Lakhs, unless otherwise stated

a. Equity share capital	Note	31 March 2019
Particulars	8	
As at 01 April 2017		800.00
Changes in equity share capital		
As at 01 April 2018		800.00
Changes in equity share capital		
As at 31 March 2019		800.00

b. Other equity

Particulars	Note	Retained Earnings	Other Comprehensive
			Income
			Exchange differences in translating the financial statements of foreign operations
As at 01 April 2017	9	(606.22)	-
Profit for the year		18.24	-
Exchange differences in translating the financial statements of foreign operations		-	-
As at 01 April 2018		(587.98)	-
Profit for the year		40.54	-
Exchange differences in translating the financial statements of foreign operations		-	0.10
As at 31 March 2019		(547.44)	0.10

The accompanying notes are an integral part of the financial statements.

As per our report of even date
 For M. Anandam & Co
 Chartered Accountants
 Firm Registration Number: 0001255
 Sd/-

A V Sadasiva
 Partner
 M.No. 018404

Place: Hyderabad
 Date: 29.05.2019

For and on behalf of the Board

Sd/-
 Vasudev Komaraju
 Wholetime Director
 DIN: 07233691

Sd/-
 Sushant Mohan Lal
 Director
 DIN: 01227151

0 0
 0 0

This page is intentionally left blank

COMBAT DRUGS LIMITED

Regd Office: 4th Floor, Plot No. 94, Sagar Society, Road No. 2, Banjara Hills, Hyderabad, Telangana-500034. India. Email: info@combatdrugs.in URL: www.combatdrugs.in
Works: 9-109/9, Plot No.112, Rd.No.14, Gayatri Nagar, Boduppal, Hyderabad-39. TS.

The Ministry of Corporate Affairs (MCA) has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the Companies vide its circular no. 17/2011 dated April 21, 2011 and 18/ 2011 dated April 29, 2011 after considering certain provisions of the Information Technology Act, 2000, permitted the companies to send the notices / annual reports etc. through email to its members. To support this green initiative of the MCA whole heartedly, members who have not yet registered their email address, are requested to register their e-mail address with the Depository through their concerned Depository Participant and members who hold shares in physical mode are requested to intimate their e-mail address at which they would like to receive the above documents electronically, either to the company or to its Registrar and Share Transfer Agent. Shareholders are requested to fill the consent form below and send it to the Registrar and Share Transfer Agent, M/s Venture Capital & Corporate Investments Private Limited or to the company.

CONSENT FOR RECEIVING DOCUMENTS IN ELECTRONIC MODE

(Pursuant to circulars no. 17/2011 dated April 21, 2011 and 18/2011 Dtd April 29, 2011)

To

M/S Venture Capital & Corporate Services Private Limited

12-10-167, Bharat Nagar, Hyderabad-500 018, Telangana

Email id: info@vccipl.com

Dear Sir,

I/We shareholder (s) of COMBAT DRUGS LIMITED, agree to receive all notices and documents including the Annual Report, Notice for General Meetings and other Shareholders Communication in electronic mode (through email).

I/We request you to kindly register my / our below mentioned email id in the company's records for sending such communication through email.

Folio No /DP ID No.* Client ID No.*

*Applicable for members holding shares in electronic form.

Name of the Sole / First Shareholder : _____

Name of the Joint Shareholders (if any) : _____

No. of Shares held : _____

E-mail id for receipt of documents in Electronic mode : _____

Date :

Place:

Signature:

(Sole / First Shareholder)

Note:

1. Shareholders are requested to inform the Company's Registrar and Share Transfer Agents Venture Capital & Corporate Investments Pvt Ltd, as and when there is change in their registered email-id.
2. For shares held in demat form, shareholders are also requested to inform /update their email-ids to their respective Depository Participants.

COMBAT DRUGS LIMITED

Regd Office: 4th Floor, Plot No. 94, Sagar Society, Road No. 2, Banjara Hills, Hyderabad, Telangana-500034. India. Email: info@combatdrugs.in URL: www.combatdrugs.in

Works: 9-109/9, Plot No.112, Rd.No.14, Gayatri Nagar, Boduppal, Hyderabad - 500039. TS. Phone: 040-48536100 Email: info@combatdrugs.in URL: www.combatdrugs.in

ATTENDANCE SLIP

33rd ANNUAL GENERAL MEETING ON 09th December, 2019

Regd. Folio No.:..... No. of Shares: **MEMBER / PROXY**

DP ID No.:..... Client ID No.:

I hereby record my presence at the 33rd ANNUAL GENERAL MEETING of the Members of Combat Drugs Limited held on 09th DECEMBER, 2019 at 11:00A.M at 1st Floor, Conference Hall, Goodlands Banquet, Opp. CCMB Habsiguda X Roads, Hyderabad-7.

Name: Name of Proxy:.....

Sign:..... Sign:.....

Note: 1. Only Members of the Company or their proxies will be allowed to attend the Meeting ON PRODUCTION OF ATTENDANCE SLIP duly completed and signed. 2. Please fill this admission slip and hand it over at the entrance of the hall duly signed. 3. Members are requested to bring their copies of Annual Report with them. 4. Members who hold shares in dematerialised form are requested to bring their Client ID and DP ID numbers for easy identification of attendance at the Meeting.

PROXY FORM

32nd ANNUAL GENERAL MEETING ON 09th DECEMBER, 2019.

Regd. Folio No.:.....No. of Shares:DP ID No.:.....Client ID No:....

I/We.....of.....in the District ofbeing a Member(s) of the above Company hereby appoint.....resident ofin the District ofas my/our Proxy to attend and to vote for me/us on my/our behalf at the 33rd Annual General Meeting of Combat Drugs Limited to be held on the 09th DECEMBER, 2019 at 11:00A.M at 1st Floor, Conference Hall, Goodlands Banquet, Opp. CCMB Habsiguda X Roads, Hyderabad-7. Telangana. and at any adjournment thereof.

Signed this..... day ofTwo Thousand and Nineteen.

I hereby record my presence at the 33rd ANNUAL GENERAL MEETING of the Members of Combat Drugs Limited held on 09th DECEMBER, 2019 at at 11:00A.M at 1st Floor, Conference Hall, Goodlands Banquet, Opp. CCMB Habsiguda X Roads, Hyderabad-7. Telangana.

Name: Name of Proxy:.....

Sign:..... Sign:.....

Affix
Revenue
Stamp

Note: 1. This Proxy Form duly completed should be deposited at the Registered Office of the Company not less than 48 (Forty Eight) hours before the time fixed for holding the meeting. 2. Only Members of the Company or their proxies will be allowed to attend the Meeting ON PRODUCTION OF ATTENDANCE SLIP duly completed and signed. 3. Please fill this admission slip and hand it over at the entrance of the hall duly signed. 4. Members are requested to bring their copies of Annual Report with them. 5. Members who hold shares in dematerialised form are requested to bring their Client ID and DP ID numbers for easy identification of attendance at the Meeting

POLLING PAPER

[Pursuant to Section 109 (5) of the Companies Act, 2013 and Rule 21 (1) (C) of the Companies (Management and Administration) Rules, 2014]

Name of the Company	: COMBAT DRUGS LIMITED 33rd AGM: 09.12.19
CIN	: CL23230TG1986PLC006781
Registered Office	: 4th Floor, Plot No.94, Sagar Society, Rd No.2, Banjara Hills, Hyderabad-34, Telangana, INDIA Phone: 040-48536100. info@combatdrugs.in
Website	: www.combatdrugs.in

BALLOT PAPER

No.	Particulars	Details
1.	Name of the First Named Shareholder (In BLOCK letters)	
2.	Postal address/E-mail address	
3.	Registered Folio No./ *DP ID and Client ID No. (*Applicable to investors holding shares in dematerialized form)	
4.	No. of Shares Held Class of Share	Equity Shares

I / We have read the detailed Resolutions presented in the Notice and the Explanatory statements thereof and hereby exercise my vote in respect of Ordinary/ Special Resolution/s enumerated in the Notice of the 33rd Annual General Meeting of the company, Combat Drugs Limited, as below, by recording my assent or dissent to the said resolution in the following manner:

Signature

BALLOT PAPER

I / We have read the detailed Resolutions presented in the Notice and the Explanatory statements thereof and hereby exercise my vote in respect of Ordinary/ Special Resolution/s enumerated in the Notice of the 33rd Annual General Meeting of the company, Combat Drugs Limited, as below, by recording my assent or dissent to the said resolution in the following manner:

I hereby exercise my vote in respect of Ordinary/ Special Resolution/s enumerated below by recording my assent or dissent to the said resolution in the following manner:

Sl. No.	Item No./Brief Heading of the proposed resolution	Type of Resolution	No. of shares held by me	I assent to the resolution	I dissent from the resolution
1.	Adoption Of Audited Accounts and Reports	Ordinary			
2.	Appointment of Auditors	Ordinary			
3	Re-Appointment of Mr. Ragu Raguram as an Independent Director	Ordinary			
4	Re-Appointment of Mrs. Vemuri Shilpa as an Independent Director	Ordinary			
5	Re-Appointment of Mr. Sushant Mohan Lal as Director	Special			
6	Approval to Change the Name of the Company	Special			
7	Approval to Increase the Authorised Capital	Special			
8	Approval for Issue of Equity Shares on Preferential Basis	Special			
9	Approval for Disinvestment of Subsidiary company M/s RA Labs Pte Ltd, Singapore	Special			

Date:

(Signature of the Shareholder)

PRINTED MATTER

If Undelivered please return to:

COMBAT DRUGS LIMITED

Regd Office: 4th Floor, Plot No.94, Sagar Society,
Rd No. 2, Banjara Hills, Hyderabad-39, Telangana, INDIA
Phone: 040-48536100., E-mail: info@combatdrugs.in